

538,231

Rec'd PCT/ 09 JUN 2005

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



10/538231



(43) International Publication Date  
24 June 2004 (24.06.2004)

PCT

(10) International Publication Number  
WO 2004/053054 A2

(51) International Patent Classification<sup>7</sup>:

C12N

(21) International Application Number:

PCT/IL2003/001040

(22) International Filing Date: 9 December 2003 (09.12.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/431,728 9 December 2002 (09.12.2002) US

(71) Applicant (for all designated States except US): NATS-PEARS LTD. [IL/IL]; 2a Katzir Street, Ramat Gan 52656 (IL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MANDELBOIM, Ofer [IL/IL]; 58 Hayarden Street, 73142 Shoam (IL). PORGADOR, Angel [IL/IL]; 11 Tavlan Street, Lehavim 85338 (IL).

(74) Agent: WEBB, Cynthia; Webb & Associates, P.O. Box 2189, Rehovot 76121 (IL).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NK CELL RECEPTOR CONJUGATES FOR TREATING MALIGNANCIES

(57) Abstract: The present invention relates generally to compositions useful in therapies involving the selective destruction of tumor cells in vivo. In particular, this invention relates to a conjugate which comprises a target recognition segment and an active cytotoxic segment. The target recognition segment comprises a receptor specific to NK cells, wherein the receptor binds to a cellular ligand expressed on the surface of a tumor cell, and the active segment comprises an agent capable of exerting a cytotoxic effect on the tumor cell. The target recognition segment derived from the natural killer receptor NKp30 has been found to be particularly effective in vivo.

WO 2004/053054 A2

## NK CELL RECEPTOR CONJUGATES FOR TREATING MALIGNANCIES

### FIELD OF THE INVENTION

The present invention relates generally to compositions useful in the treatment 5 of various cancers and to therapies involving the selective destruction of tumor cells in vivo. More specifically, the present invention relates to conjugates and fusion proteins of Natural Killer cytotoxicity receptors NKp30, NKp46 and NKp44, or active fragments thereof and an active agent selected from a cytotoxic drug or an Ig fragment effective in targeting tumor cells in vivo. Particularly preferred compositions are conjugates and 10 fusion proteins of the NK cell specific receptor NKp30 with the Fc fragment of an Ig molecule.

### BACKGROUND OF THE INVENTION

A key to the development of successful antitumor agents is the ability to design 15 agents that will kill tumor cells selectively, while exerting relatively little, if any, untoward effects against normal tissues. This goal has been elusive to achieve, in that there are few qualitative differences between neoplastic and normal tissues. Because of this, much research over the years has focused on identifying tumor-specific antigens that can serve as immunological targets both for chemotherapy and diagnosis. Many tumor- 20 specific, or quasi-tumor-specific ("tumor-associated"), markers have been identified as tumor cell antigens that can be recognized by specific antibodies. Unfortunately, it is generally the case that tumor-specific antibodies of themselves will not exert sufficient antitumor effects to make them useful in cancer therapy.

25 Natural Killer (NK) cells destroy virus-infected and transformed cells apparently without prior antigen stimulation (1, 2). The interaction between NK cells and their targets is mediated via a complex array of NK inhibitory and activating receptors (3-7). Heavily implicated in this interplay are inhibitory receptors of the NK cell surface, the ligands of which are polymorphic and non-polymorphic major histocompatibility 30 complex (MHC) class I molecules (3-7). With regard to activation, some NK cells express activation receptors specific for MHC class I molecules homologous to various NK inhibitory receptors (3-7).

Three novel lysis receptors, expressed mainly on human NK cells, were recently identified. These natural cytotoxicity receptors (NCR) include the NKp30, NKp44, and NKp46 molecules (3, 5). All of these NCR are capable of mediating direct killing of tumor and virus-infected cells and are specific for non-MHC ligands. NKp46 and NKp30 5 are present exclusively on NK cells, whether resting or activated, while NKp44 is expressed specifically by activated NK cells (3, 5).

The most distinctive role of the NCRs in NK cells activity has been attributed to their involvement in recognition and killing of tumor cells. This has become evident by 10 the ability of anti-NCR monoclonal antibodies to block NK-mediated killing of most tumor lines (8-11) and by the strict correlation that exists between the density of NCRs expression on NK cells and their ability to kill tumor targets (11). More recently, the importance of NCRs in vivo was illustrated in acute myeloid leukemia (AML) patients expressing insufficient amount of either NCR or NCR ligands, thereby rendering the 15 leukemia cells resistant to NK cytotoxicity (12).

International Patent Application WO 02/08287 of the present inventors discloses 20 NK receptor fusion proteins in which the extracellular portion of the various NK receptors is conjugated to an active segment selected from an immunoglobulin (Ig) or Ig fragment, a cytotoxic moiety or an imaging moiety. WO 02/08287 further discloses that the NK receptor fusion proteins exhibit specific interactions with tumor cells and viral-infected cells, and these fusion proteins are disclosed as useful for therapeutic 25 applications ex vivo, as well as in vivo. WO 02/08287 generally discloses fusion proteins comprising any one of the three NK cytotoxicity receptors, namely NKp46, NKp44 and NKp30. Specific fusion proteins are disclosed and claimed only for NKp46 and NKp44. The teachings of WO 02/08287 are incorporated herein as if set forth herein in their entirety. It is to be understood explicitly that the present invention excludes any of the 30 specific compositions claimed in WO 02/08287.

WO 01/36630 discloses NKp30, and the use of NKp30 for detecting NK cells and for selective removal of NK cells from a sample. WO 01/36630 further discloses the use of NKp30 antiserum for in vitro stimulation of NK cells cytotoxicity. WO 01/36630 neither discloses nor teaches any therapeutic utility of NKp30 against malignant diseases

or even specific targeting of a tumor cell *in vivo* using either NKp30 or NKp30 fusion proteins.

5 There exists a long-felt need for anti-tumor agents that will be selective for tumor cells, while exerting relatively little, if any, untoward effects against normal tissues.

### SUMMARY OF THE INVENTION

It is an object of the present invention to provide compositions and methods for inhibiting or reducing the growth of a tumor in a patient. It is a further object of the 10 present invention to provide compositions and therapeutic methods for selectively lysing tumor cells or for selectively delivering a cytotoxic drug to a target tumor cell in a patient for the purpose of eliminating the target tumor cell either directly or by creating an environment lethal to the target cell.

15 The present invention relates generally to Natural Killer Cytotoxicity receptor (NCR) conjugates and fusion proteins that are effective in targeting tumor cells *in vivo*. The present invention further relates to NCR conjugates and fusion proteins that are effective in inhibiting the growth of the tumor or reducing the size of the tumor.

20 The NCR conjugates or fusion proteins according to the present invention comprise a first segment comprising an NCR selected from the group consisting of: NKp46, NKp44 and NKp30, or active fragments thereof, and a second segment comprising an agent active in inducing cytotoxicity. The conjugates or fusion proteins according to the invention comprise an active segment selected from a cytotoxic substance, an 25 Immunoglobulin (Ig) molecule or an active fragment of an Ig molecule such as the Fc fragment of Ig. It is to be understood explicitly that the present invention discloses and claims certain novel conjugates and fusion proteins, particularly those comprising NKp30 or active fragments thereof.

30 Unexpectedly, it is now disclosed that of the various NK conjugates and fusion proteins tested, those comprising the natural killer cytotoxicity receptor NKp30 or active fragments thereof were found to be especially effective in inhibiting the growth of tumors *in vivo*. As exemplified herein below by way of a non-limiting example, NKp30 conjugates according to the present invention were particularly effective in inhibiting

growth of PC3 prostate tumor cells *in vivo* as compared to NKp46 and NKp44 conjugates.

According to one aspect, the present invention provides a polypeptide conjugate and 5 pharmaceutical compositions comprising same, wherein the polypeptide conjugate comprises as a first segment an NCR or fragments thereof and as a second segment an agent active in inducing cytotoxicity.

According to one embodiment, the present invention provides a polypeptide 10 conjugate comprising a first segment selected from the group consisting of: NKp30, NKp44, NKp46 or a functional fragments thereof; and a second segment selected from the group consisting of: an Ig molecule, a fragment of an Ig molecule and an Fc portion of an Ig molecule.

15 According to a preferred embodiment, the polypeptide conjugate comprises NKp30 or a functional fragment thereof and an Fc portion of an Ig molecule.

According to a currently preferred embodiment, the polypeptide conjugate comprises the amino acid sequence set forth herein as SEQ ID NO:4.

20

According to yet another embodiment, the present invention provides a pharmaceutical composition comprising as an active ingredient a conjugate capable of eliminating a tumor or inhibiting the growth of the tumor in a subject, and a pharmaceutically acceptable carrier, the conjugate comprising:

25 (a) a target recognition segment comprising an NCR or an active fragment thereof, the NCR selected from the group consisting of: NKp30, NKp46, and NKp44, or a functional fragment thereof, wherein the NCR binds to a cellular ligand expressed on the surface of a target tumor cell;

30 (b) an active segment comprising a cytotoxic agent that promotes the lysis of the target tumor cell; and

(c) a pharmaceutically acceptable carrier or diluent.

According to one preferred embodiment of the invention the pharmaceutical composition comprises as an active ingredient a polypeptide conjugate comprising NKp30 or a functional fragment thereof and an Fc portion of an Ig molecule.

5 According to a currently preferred embodiment, the pharmaceutical composition comprises as an active ingredient a polypeptide conjugate having the sequence set forth herein as SEQ ID NO:4.

10 According to another aspect, the present invention provides isolated polynucleotides encoding the polypeptide conjugates of the present invention, constructs comprising the polynucleotides, vectors comprising these constructs, hosts cells harboring these vectors, and means of producing the polypeptides from cultures of these host cells.

15 According to one embodiment, the present invention provides an isolated polynucleotide sequence encoding the polypeptide conjugate of the invention.

According to another embodiment, the isolated polynucleotide encodes a polypeptide conjugate comprising NKp30 or a functional fragment thereof and an Fc portion of an Ig molecule.

20

According to one preferred embodiment, the polynucleotide encodes a polypeptide having the sequence set forth herein as SEQ ID NO:4.

25 According to a currently preferred embodiment, the polynucleotide comprises the sequence set forth herein as SEQ ID NO:11, or a functional fragment thereof.

According to yet another embodiment, the present invention provides a vector comprising a polynucleotide encoding a polypeptide conjugate comprising NKp30 or a functional fragment thereof and an Fc portion of an Ig molecule.

30

According to yet another embodiment, the vector is a plasmid or a virus. According to yet another embodiment, the vector is a virus selected from the group consisting of: adenoviruses, retroviruses and lentiviruses.

According to yet another embodiment, the vector further comprises at least one regulatory element operably linked to the polypeptide conjugate of the invention, the at least one regulatory element is selected from the group consisting of: promoter, initiation codon, stop codon, polyadenylation signal, enhancer and selection marker.

5

According to one embodiment, the present invention provides a host cell comprising the vector of the invention. According to another embodiment the host cell is eukaryotic or prokaryotic. According to yet another embodiment, the present invention provides a host cell capable of expressing the polypeptide conjugate of the invention.

10

According to yet another aspect, the present invention provides a method for treating a malignant disease in a subject comprising administering to the subject a pharmaceutically effective amount of a polypeptide conjugate comprising:

15      a) a target recognition segment comprising a Natural Killer cytotoxic receptor (NCR) or an active fragment thereof, wherein the NCR is selected from the group consisting of: NKp46, NKp44, NKp30 or a functional fragment thereof, that binds to a cellular ligand expressed on the surface of a target tumor cell; and  
20      b) an active segment comprising an active agent, the active agent being capable of exerting a cytotoxic effect on said target cell,

the conjugate being capable of eliminating or inhibiting the growth of the tumor cells associated with the disease, thereby treating the disease.

25      According to a currently preferred embodiment of the invention the polypeptide conjugate used in this method comprises NKp30 and an Fc portion of an Ig molecule having the sequence set forth herein as SEQ ID NO:4.

30      According to yet another aspect, the present invention provides a method of inhibiting the growth of a tumor in a subject comprising administering to the subject an effective amount of a polypeptide conjugate comprising:

a) a target recognition segment comprising an NCR or an active fragment thereof, wherein said NCR is selected from the group consisting of: NKp46, NKp44, NKp30 or a functional fragment thereof, wherein the target recognition segment is

capable of binding to a cellular ligand expressed on the surface of a target tumor cell,; and

b) an active segment comprising an active agent that promotes the lysis of the target tumor cell, thereby inhibiting the growth of the tumor in said subject.

5

According to a currently preferred embodiment of the invention the polypeptide conjugate used in this method comprises NKp30 and an Fc portion of an Ig molecule having the sequence set forth herein as SEQ ID NO:4.

10 It is noted that in certain cases, the conjugates of the present invention are capable of eliminating the tumor to the extent that there is no gross evidence for the presence of a tumor in the subject. In other cases, the conjugates of the present invention are capable of reducing the size of the tumor significantly. Preferably the conjugates are capable of reducing the size of a solid tumor by 50% of the initial size, more preferably to 30% of  
15 the initial size, most preferably to 10% of the initial size. The size of the tumor in the subject may be determined by any of the diagnostic or imaging techniques as are well known in the art, including for example by Computed Tomography Imaging (CT) or Magnetic Resonance Imaging (MRI).

20 The NCR conjugates according to the present invention comprise an NCR selected from the group consisting of: NKp30, NKp46 and NKp44, or active fragments thereof. The conjugates according to the invention further comprise an active segment that is selected from a cytotoxic substance, an Immunoglobulin (Ig) molecule or an active fragment of the Ig including but not limited to the Fc fragment of Ig.

25

According to one exemplary embodiment, the NCR conjugate comprises NKp46 covalently attached to the Fc portion of an Ig molecule, the amino acid sequence of which is denoted as SEQ ID NO:1 and the nucleotide sequence of which is denoted as SEQ ID NO:8. In a preferred embodiment, the NCR conjugate comprises the domain 2 (D2 domain) of NKp46 covalently attached to the Fc molecule, the amino acid sequence of which is denoted as SEQ ID NO:3 and the nucleotide sequence of which is denoted as SEQ ID NO:10. It is noted that while both Isoform A and Isoform B of NKp46 may be used in the conjugates of the invention, the A Isoform is preferred.

According to one currently more preferred embodiment, the NCR conjugate comprises NKp30 covalently attached to the Fc portion of an Ig molecule, the amino acid sequence of which is set forth herein as SEQ ID NO:4 and the nucleotide sequence of which is set forth herein as SEQ ID NO:11. This NKp30-Fc conjugate was unexpectedly 5 discovered to be very effective in inhibiting the growth of a tumor *in vivo*. It is to be understood explicitly that any analog, derivative or other conjugate having the same attributes is encompassed within the scope of the present invention.

According to yet another embodiment, the NCR conjugate comprises NKp44 10 covalently attached to Fc molecule, the amino acid sequence of which is denoted as SEQ ID NO:5 and the nucleotide sequence of which is denoted as SEQ ID NO:12.

According to yet another embodiment, the NCR conjugate comprises the NK44-DS fragment covalently attached to Fc molecule, the amino acid sequence of 15 which is denoted as SEQ ID NO:6 and the nucleotide sequence of which is denoted as SEQ ID NO:13. In yet another embodiment, the NCR conjugate comprises the NK44-DL fragment covalently attached to Fc molecule, the amino acid sequence of which is denoted as SEQ ID NO:7 and the nucleotide sequence of which is denoted as SEQ ID NO:14.

20

As noted above, certain preferred conjugates according to the present invention comprise the Fc fragment of an immunoglobulin molecule as the active segment. The Fc conjugates to the natural killer cytotoxicity receptors is therapeutically useful irrespective of any specific mechanism of action. Without wishing to be bound by any theory, the 25 binding of the Fc-containing conjugates to the target tumor cell can potentially induce cell lysis via three possible mechanisms:

- 1) Cellular Cytotoxicity - Several different leukocytes including neutrophils, eosinophils, macrophages and NK cells contain Fc receptors and are capable of binding to conjugate-bound tumor cells via the Fc segment, resulting in the lysis of the tumor 30 cells.
- 2) Complement-Dependent Cytotoxicity- The lysis of the conjugate-bound target tumor cells may be mediated by activation of the complement pathway.

3) Induction of programmed cell death (Apoptosis) following the binding of the Fc-containing conjugates to the target tumor cells and activation of apoptosis intracellular signaling pathways leading to cell death.

5 According to yet another aspect, the present invention provides a method of delivering a cytotoxic substance to a target tumor cell in a subject in need thereof comprising:

10 b. administering to the subject a therapeutically effective amount of a conjugate comprising a first segment being a target recognition segment comprising an NCR or an active fragment thereof, the NCR selected from the group consisting of NKp46, NKp44, NKp30 or a functional fragment thereof, and a second segment comprising a cytotoxic agent, the target recognition segment capable of binding to a cellular ligand expressed on the surface of said target tumor cell, wherein the binding of the conjugate to the cellular ligand promotes the internalization of said conjugate into said target tumor cell, thereby 15 delivering said cytotoxic agent to said target tumor cell.

According to one preferred embodiment, the conjugate for delivering a cytotoxic substance to a target tumor cell in a subject comprises NKp30 or an active fragment thereof. According to additional preferred embodiments, the conjugate for 20 delivering a cytotoxic substance to a target tumor cell in a subject comprises NKp46 or domain 2 of NKp46 covalently linked to a cytotoxic substance. The advantage of the conjugates of the present invention is that the binding of the conjugate to the cellular ligand promotes the internalization of said conjugate within said target tumor cell. Thus, it is preferred that the conjugates comprise a cytotoxic agent which promotes cell death 25 upon internalization of the cytotoxic agent into the cell. Preferred cytotoxic agents include, but are not limited to, radioisotopes, steroids, chemotherapeutic drugs, and antisense oligonucleotides.

According to one embodiment, the chemotherapeutic agents are selected from 30 the group consisting of: a hormone such as a steroid; an antimetabolite such as cytosine arabinoside, fluorouracil, methotrexate or aminopterin; an anthracycline; mitomycin C; a vinca alkaloid; demecolcine; etoposide; mithramycin; an antitumor alkylating agent such as chlorambucil. Other drugs such as busulfan, carmustine, cisplatin, cyclophosphamide,

doxorubicin, ifosfamide, nitrogen mustards, nitrosureas, melphalan or antitumor antibiotics such as bleomycin or daunorubicin may be used..

According to another embodiment, the radioisotope agents for therapeutic use  
5 may be for example: iodine<sup>131</sup>, iodine<sup>123</sup>, technecium<sup>99m</sup>, indium<sup>111</sup>, rhenium<sup>188</sup>,  
rhenium<sup>186</sup>, gallium<sup>67</sup>, copper<sup>67</sup>, yttrium<sup>90</sup>, iodine<sup>125</sup> or astatine<sup>211</sup>.

According to another embodiment, the cytotoxic substance may be a cytotoxin  
such as a plant-, fungus- or bacteria-derived toxin. For example, a ribosome inactivating  
10 protein,  $\alpha$ -sarcin, aspergillin, restrictocin, a ribonuclease, diphtheria toxin or  
pseudomonas exotoxin may be used as a cytotoxic substance.

It is proposed that the various methods and compositions of the present  
invention will be broadly applicable to the treatment of any tumor, including solid and  
15 non-solid tumors. If the neoplastic tissue is a part of the lymphatic or immune systems,  
the non-solid tumors may include circulating malignant cells. Malignancies of other  
tissues or organs may produce solid tumors. In one preferred example, the conjugates  
according to the present invention are useful in the treatment of a neoplastic disease  
associated with solid tumors including but not limited to prostate cancer, melanoma,  
20 colon cancer, breast cancer, pancreatic cancer, ovarian cancer, osteosarcoma and renal  
cell carcinoma.

These and further embodiments will be apparent from the detailed description and  
examples that follow.

25

#### BRIEF DESCRIPTION OF THE DRAWINGS

**Figure 1** demonstrates the binding of NKp46, NKp44, or NKp30 conjugates to various  
cancer cells but not to normal peripheral blood lymphocytes (PBL).

30

**Figure 2** demonstrates the binding of the NKp46-D1-Ig and NKp46-D2-Ig conjugates to  
melanoma cell lines and prostate cancer cell lines.

**Figure 3** demonstrates the killing of human prostate cancer cells by NKp30-Ig and NKp46D2-Ig.

**Figure 4** demonstrates NKp30-Ig-mediated tumor regression in nude mice.

5

**Figure 5** illustrates the complete or partial response obtained by the NKp30-Ig conjugate as revealed by the size of the tumor.

10 **Figure 6** demonstrates that NKp46D2-Ig conjugate binds to the cell surface of 1106mel cells and then internalized to the intracellular domain.

15 **Figure 7** demonstrates a strong binding of NKp46D2-Ig and NKp30-Ig to a tissue section derived from adenomacarcinoma but not to a tissue section derived from benign prostatic hyperplasia (BPH).

20 **Figure 8** demonstrates that NKp30-Ig and NKp46D2-Ig bind to a tissue section derived from malignant melanoma but not to a tissue section derived from benign nevus tissue.

25 **Figure 9** demonstrates that NKp46D2-Ig specifically binds to a tissue section derived from pancreatic cancer.

#### **DETAILED DESCRIPTION OF THE INVENTION**

In order that this invention may be better understood, the following terms and definitions are herein provided.

25

The term "specific binding" as used herein refers to the preferential association of a molecule with a cell or tissue bearing a particular target molecule or marker and not to cells or tissues lacking that target molecule or expressing that target molecule at low levels. It is, of course, recognized that a certain degree of non-specific interaction may 30 occur between a molecule and a non-target cell or tissue.

The term "conjugate" refers to a polypeptide formed by the joining of two or more polypeptides through a peptide bond formed between the amino terminus of one polypeptide and the carboxyl terminus of another polypeptide. The conjugate may be

formed by the chemical coupling of the constituent polypeptides or it may be expressed as a single polypeptide fusion protein from a nucleic acid sequence encoding the single contiguous conjugate. In those instances where the active segment of the conjugate is a cytotoxic agent that is not a polypeptide it is to be understood that the cytotoxic agent is 5 attached via chemical coupling to the polypeptide.

The term "cellular ligand" refers generally to tumor cell membrane molecules capable of reacting with the target recognition segment of the conjugate of the invention.

10 The term "target recognition segment" refers to a targeting segment capable of specifically recognizing and binding to a target tumor cell via its cellular ligand.

15 The term "delivering a cytotoxic substance to a target tumor cell" means that the amount of substance associated with a target tumor cell is at least two-fold, preferably 5-fold, more preferably 10-fold higher than the amount of the substance associated with a normal cell.

20 The term "target cells" refers to cells that are killed by the cytotoxic activity of the conjugate of the invention. The target cells express the ligand for at least one of NKp46, NKp44 and NKp30 molecules and include, in particular, cells that are malignant or otherwise derived from solid as well as non-solid tumors.

25 The terms "NKp30, NKp44, and NKp46" refer to natural cytotoxicity receptors expressed on human NK cells which are capable of mediating direct killing of tumor and virus-infected cells.

30 The term "active fragments" refers to "fragments", "variants", "analogs" or "derivatives" of the molecule. A "fragment" of a molecule, such as any of the nucleic acid or the amino acid sequence of the present invention is meant to refer to any nucleotide or amino acid subset of the molecule. A "variant" of such molecule is meant to refer to a naturally occurring molecule substantially similar to either the entire molecule or a fragment thereof. An "analog" of a molecule is a homologous molecule from the same species or from different species. The amino acid sequence of an analog or derivative may differ from the specific molecule, e.g. the NKp46, NKp30 or NKp44

molecule, used in the present invention when at least one residue is deleted, inserted or substituted.

5        The term "cytotoxic effect" refers to a killing of target cells by any of a variety of biological, biochemical, or biophysical mechanisms. Cytolysis refers more specifically to activity in which the effector lyses the plasma membrane of the target cell, thereby destroying its physical integrity. This results in the killing of the target cell.

10      The term "complement-mediated lysis" refers to the process by which the complement-dependent coagulation cascade is activated, multi-component complexes are assembled, ultimately generating a lytic complex that has direct lytic action, causing cell permeabilization.

15      The term "cell-mediated cytotoxicity or destruction" refers to antibody-dependent, cell-mediated cytotoxicity (ADCC) and natural killer (NK) cell killing.

20      The present invention provides a method for treating a subject having a tumor using an NCR conjugate for specific targeting of tumor cells *in vivo*. The NCR conjugate of the invention comprises a target recognition segment and an active segment. The target recognition segment comprises a receptor specific to NK cells or a fragment thereof, wherein the receptor binds to a cellular ligand expressed on the surface of a tumor cell, and the active segment comprises an active substance, said active substance is capable of exerting a cytotoxic effect on the tumor cell.

25      The method of the invention relates to a specific elimination of tumor cells *in vivo*, and comprises administering to a subject at least one dose of a pharmaceutically effective amount of the NCR conjugate of the invention. The "pharmaceutically effective amount" is an amount of the NCR conjugate effective to specifically kill at least a portion, and preferably a significant portion, of the tumor cells, upon binding of the NCR conjugate to a cellular ligand expressed on the surface of said tumor cells.

30      In one embodiment, the NCR conjugate comprises NKp46 covalently attached to Fc molecule, the amino acid sequence of which is denoted as SEQ ID NO:1 and the nucleotide sequence of which is denoted as SEQ ID NO:8. In a preferred embodiment,

the NCR conjugate comprises the domain 2 (D2 domain) of NKp46 covalently attached to the Fc molecule, the amino acid sequence of which is denoted as SEQ ID NO:3 and the nucleotide sequence of which is denoted as SEQ ID NO:10. It is noted that while both Isoform A and Isoform B of NKp46 may be used in the conjugates of the invention, the A 5 Isoform is preferred.

In more preferred embodiment, the NCR conjugate comprises NKp30 covalently attached to Fc molecule, the amino acid sequence of which is denoted as SEQ ID NO:4 and the nucleotide sequence of which is denoted as SEQ ID NO:11. The 10 NKp30-Fc conjugate was unexpectedly discovered to be very effective in inhibiting the growth of a tumor in vivo.

In yet another embodiment, the NCR conjugate comprises NKp44 covalently attached to Fc molecule, the amino acid sequence of which is denoted as SEQ ID NO:5 and the nucleotide sequence of which is denoted as SEQ ID NO:12. In yet another embodiment, the NCR conjugate comprises the NK44-DS fragment covalently attached to Fc molecule, the amino acid sequence of which is denoted as SEQ ID NO:6 and the nucleotide sequence of which is denoted as SEQ ID NO:13. In yet another embodiment, the NCR conjugate comprises the NK44-DL fragment covalently attached to Fc 20 molecule, the amino acid sequence of which is denoted as SEQ ID NO:7 and the nucleotide sequence of which is denoted as SEQ ID NO:14.

A further aspect the invention relates to a pharmaceutical composition comprising as an active ingredient a conjugate comprising:  
25 a target recognition segment comprising an NCR or an active fragment thereof, the NCR selected from the group consisting of: NKp46, NKp44, NKp30 or a functional fragment thereof that binds to a cellular ligand expressed on the surface of a target tumor cell; and  
an active segment comprising an active agent that promotes the lysis of the target tumor 30 cell;  
and a pharmaceutically acceptable carrier, stabilizer or diluent.

The active segment of the composition of the invention may be an Ig fragment, preferably the Fc portion of an Ig molecule. Alternatively, the active segment may be a

cytotoxic substance, such as a chemotherapeutic agent, a radiotherapeutic agent or a cytotoxin capable of exerting a cytotoxic effect on the tumor cell.

5 In preferred embodiments, the method of the invention includes administering to a subject in need a pharmaceutical composition comprising an amount of NCR-Ig conjugate effective to induce specific cytotoxicity in tumor cells or other diseased cells.

10 Without wishing to be bound by any particular theory or mechanism of action, according to one embodiment the cytotoxicity may be Antigen-Dependent Cellular Cytotoxicity (ADCC). Specifically, the NCR-Ig conjugates can induce the activation of immune cells that are equipped with Fc or complement receptors, such as macrophages and NK cells. These cells are capable of binding to the NCR-Ig conjugate-coated tumor cells and eliminate them via phagocytosis or via cell-mediated cytotoxicity.

15 According to an alternative embodiment, the NCR-Ig conjugates of the present invention may also activate the complement-mediated lysis of at least a portion of the tumor cells. The complement system is activated principally by the binding of the first classical pathway component, C1, to the Fc portion of antigen-complexed antibody molecules. Therefore, the conjugates comprising NKp30, NKp46 or NKp44, and the Fc 20 portion of an Ig molecule, can serve as target for the complement system *in vivo*.

25 In another embodiment, the method of the invention employs a conjugate wherein the NCR is covalently attached to a cytotoxic substance. According to the principles the conjugates of the invention encompass the use of any cytotoxic substance or agent that can be conjugated to the target recognition segment of an NCR, and can be thus targeted or delivered in active form to the target cell. In any event, it is proposed that cytotoxic agents may be successfully conjugated to the targeting segment in a manner that will allow their targeting, internalization, release or presentation to the target cells as required. Conjugation may be accomplished using any known conjugation technologies 30 as are well known in the art [for example, Ghose, *et al.*, Critical Reviews in Therapeutic Drug Carrier Systems, 3:256-359 (1987)].

It is to be appreciated that the targeting segment of the conjugate of the invention may be linked to the active segment, either directly or indirectly by conjugating or coupling these segments to any one of lipid backbone or carbohydrate backbone.

5           Exemplary cytotoxic substances include chemotherapeutic agents, radioisotopes as well as cytotoxins. In one embodiment, the chemotherapeutic agents are selected from the group consisting of: a hormone such as a steroid; an antimetabolite such as cytosine arabinoside, fluorouracil, methotrexate or aminopterin; an anthracycline; mitomycin C; a vinca alkaloid; demecolcine; etoposide; mithramycin; an antitumor 10 alkylating agent such as chlorambucil. Other drugs such as busulfan, carmustine, cisplatin, cyclophosphamide, doxorubicin, ifosfamide, nitrogen mustards, nitrosureas, melphalan or antitumor antibiotics such as bleomycin or daunorubicin may be used..

15           In another embodiment, the radioisotope agents for therapeutic use may be for example: iodine<sup>131</sup>, iodine<sup>123</sup>, technecium<sup>99m</sup>, indium<sup>111</sup>, rhenium<sup>188</sup>, rhenium<sup>186</sup>, gallium<sup>67</sup>, copper<sup>67</sup>, yttrium<sup>90</sup>, iodine<sup>125</sup> or astatine<sup>211</sup>.

20           In another embodiment, the cytotoxic substance may be a cytotoxin such as a plant-, fungus- or bacteria-derived toxin. For example, a ribosome inactivating protein,  $\alpha$ -sarcin, aspergillin, restrictocin, a ribonuclease, diphtheria toxin or pseudomonas exotoxin may be used as a cytotoxic substance.

25           Particularly preferred cytotoxins include Pseudomonas exotoxins, Diphtheria toxins, ricin, abrin, cytotoxic prodrugs, ribonucleases (e.g., Ribonuclease A), and ribozymes. Pseudomonas exotoxin and Diphtheria toxin, doxorubicin and maytansinoids are most preferred. Pseudomonas exotoxin A (PE) is an extremely active monomeric protein (molecular weight 66 kD), secreted by Pseudomonas aeruginosa, which inhibits protein synthesis in eukaryotic cells. Like PE, diphtheria toxin (DT) kills cells by ADP-ribosylating elongation factor 2 thereby inhibiting protein synthesis.

30

          In another embodiment, the cytotoxic moiety is a cytotoxic prodrug. The conjugate molecule bearing the prodrug is contacted with the target tumor cell thereby localizing the prodrug at the tumor site. The prodrug is then contacted with its corresponding conversion enzyme thereby converting the prodrug into its cytotoxic form

at the tumor site thereby causing the inhibition of growth or killing of tumor cells. Suitable prodrugs are well known to those of skill in the art and include, for example, etoposide-4' phosphate or 7-(2' aminoethyl phosphate)mitomycin which are activated in the presence of alkaline phosphatase (AP) to effect killing of tumor cells. Other prodrugs 5 include the prodrug N-(p-hydroxyphenoxyacetyl)adriamycin which is used in conjunction with penicillin V amidase (PVA) or 5-fluorocytosine which is used in conjunction with cytosine deaminase (CD) (see, e.g., U.S. Pat. No. 4,957,278).

10 Ricin and abrin are plant derived cytotoxins well known to those of skill in the art. Like *Pseudomonas* exotoxin and *Diphtheria* toxin, ricin and abrin can also be linked to a targeting moiety for specific delivery to cell bearing a particular target molecule. Means of joining ricin and abrin to a targeting molecule are well known to those of skill in the art (see, e.g., Pastan et al. *Ann. Rev. Biochem.*, 61: 331-354 (1992), Thrush et al., *Ann. Rev. Imm.* 14: 49-71 (1996) and references cited therein).

15

In another embodiment, the cytotoxic moiety may be an antisense oligonucleotide molecule capable of hybridizing to specific ribonucleotide sequence within the cell, thereby inhibiting the expression of the protein encoded by this ribonucleotide sequence. Antisense oligonucleotides have been safely and effectively 20 administered to humans for inhibiting the expression of specific proteins in the cell. It is thus established that oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment regimes for treatment of cells, tissues and animals, especially humans. In the context of this invention, the term "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or 25 mimetics thereof. This term includes oligonucleotides composed of naturally-occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally-occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for 30 nucleic acid target and increased stability in the presence of nucleases.

It is proposed that the various methods and compositions of the invention will be broadly applicable to the treatment of any tumor, including solid and non-solid tumors. If the tissue is a part of the lymphatic or immune systems, malignant cells may include

non-solid tumors of circulating cells. Malignancies of other tissues or organs may produce solid tumors. Exemplary solid tumors to which the present invention is directed include but are not limited to carcinomas of the lung, breast, ovary, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, 5 endometrium, kidney, bladder, prostate, thyroid, squamous cell carcinomas, adenocarcinomas, small cell carcinomas, melanomas, gliomas, neuroblastomas, and the like. Exemplary non-solid tumors to which the present invention is directed include but are not limited to B cell Lymphoma, T cell Lymphoma, or Leukemia such as Chronic Myelogenous Leukemia.

10

In a preferred embodiment, the conjugates of the present invention are synthesized using recombinant DNA methodology. Generally this involves creating a DNA sequence that encodes the conjugate, placing the DNA in an expression cassette under the control of a particular promoter, expressing the protein in a host, isolating the 15 expressed protein and, if required, renaturing the protein.

DNA encoding the conjugates of this invention may be prepared by any suitable method, including, for example, cloning and restriction of appropriate sequences or direct chemical synthesis by methods such as the phosphotriester method of Narang et 20 al. *Meth. Enzymol.* 68: 90-99 (1979); the phosphodiester method of Brown et al., *Meth. Enzymol.* 68: 109-151 (1979); the diethylphosphoramide method of Beaucage et al., *Tetra. Lett.*, 22: 1859-1862 (1981); and the solid support method of U.S. Pat. No. 4,458,066.

25 Chemical synthesis produces a single stranded oligonucleotide. This may be converted into double stranded DNA by hybridization with a complementary sequence, or by polymerization with a DNA polymerase using the single strand as a template. One of skill would recognize that while chemical synthesis of DNA is limited to sequences of about 100 bases, longer sequences may be obtained by the ligation of shorter sequences. 30 Alternatively, subsequences may be cloned and the appropriate subsequences cleaved using appropriate restriction enzymes. The fragments may then be ligated to produce the desired DNA sequence.

The nucleic acid sequences encoding the conjugates may be expressed in a variety of host cells, including *E. coli*, other bacterial hosts, yeast, and various higher eukaryotic cells such as the COS, CHO and HeLa cells lines and myeloma cell lines. The recombinant protein gene will be operably linked to appropriate expression control sequences for each host. For *E. coli* this includes a promoter such as the T7, trp, or lambda promoters, a ribosome binding site and preferably a transcription termination signal. For eukaryotic cells, the control sequences will include a promoter and preferably an enhancer derived from immunoglobulin genes, SV40, cytomegalovirus, etc., and a polyadenylation sequence, and may include splice donor and acceptor sequences.

10

Once expressed, the recombinant fusion proteins can be purified according to standard procedures of the art, including ammonium sulfate precipitation, affinity columns, column chromatography, gel electrophoresis and the like (see, generally, R. Scopes, *Protein Purification*, Springer-Verlag, N.Y. (1982), Deutscher, *Methods in Enzymology* Vol. 182. *Guide to Protein Purification*., Academic Press, Inc. N.Y. (1990)). Substantially pure compositions of at least about 90 to 95% homogeneity are preferred, and 98 to 99% or more homogeneity are most preferred for pharmaceutical uses. Once purified, partially or to homogeneity as desired, the polypeptides may then be used therapeutically.

20

The composition of the invention further comprises a pharmaceutically acceptable diluent or carrier. The compositions according to the invention will in practice normally be administered orally or by injection. As used herein "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic composition is contemplated.

30

For oral administration tablets and capsules may contain conventional excipients, such as binders, for example syrup, sorbitol, or polyvinyl pyrrolidone; fillers, for example lactose, microcrystalline cellulose, corn starch, calcium phosphate or sorbitol; lubricants, for example magnesium stearate, stearic acid, polyethylene glycol or

silica; disintegrates, for example potato starch or sodium starch glycolate, or surfactants, such as sodium lauryl sulphate.

5 Oral liquid preparations can be in the form of for example water or oil suspensions, solutions, emulsions, syrups or elixirs, or can be supplied as a dry product for constitution with water or another suitable vehicle before use.

10 The conjugate molecules of this invention are useful for parenteral, topical, oral, or local administration, such as by aerosol or transdermally. The pharmaceutical compositions can be administered in a variety of unit dosage forms depending upon the method of administration; for example oral administration include powder, tablets, pills, capsules and lozenges. It is recognized that the pharmaceutical compositions of this invention, when administered orally, must be protected from digestion. This is typically accomplished either by complexing the conjugate with a composition to render it resistant 15 to acidic and enzymatic hydrolysis or by packaging the conjugate in an appropriately resistant carrier such as a liposome. Means of protecting proteins from digestion are well known in the art.

20 The pharmaceutical compositions of this invention are particularly useful for parenteral administration, such as intravenous administration or administration into a body cavity or lumen of an organ. The compositions for administration will commonly comprise a solution of the conjugate molecule dissolved in a pharmaceutically acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers can be used, e.g., buffered saline and the like. These solutions are sterile and generally free of undesirable 25 matter. These compositions may be sterilized by conventional, well-known sterilization techniques. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, for example, sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like. The 30 concentration of the conjugate in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight and the like in accordance with the particular mode of administration selected and the patient's needs.

Thus, a typical pharmaceutical composition for intravenous administration would be about 0.1 to 10 mg per patient per day. Dosages from 0.1 up to about 100 mg per patient per day may be used, particularly when the drug is administered to a secluded site and not into the blood stream, such as into a body cavity or into a lumen of an organ.

5 Actual methods for preparing parenterally administrable compositions will be known or apparent to those skilled in the art and are described in more detail in such publications as Remington's Pharmaceutical Science, 18th ed., Mack Publishing.

10 In therapeutic applications, compositions are administered to a patient suffering from a disease, in an amount sufficient to cure or at least partially arrest the disease and its complications. An amount adequate to accomplish this is defined as a "therapeutically effective dose." Amounts effective for this use will depend upon the severity of the disease and the general state of the patient's health. Single or multiple administrations of the compositions may be administered depending on the dosage and 15 frequency as required and tolerated by the patient. In any event, the composition should provide a sufficient quantity of the proteins of this invention to effectively treat the patient.

20 One of skill in the art will appreciate that the therapeutic compositions of this invention can be administered directly to the tumor site. Thus, for example, brain tumors (e.g., gliomas) can be treated by administering the therapeutic composition directly to the tumor site (e.g., through a surgically implanted catheter). Where the fluid delivery through the catheter is pressurized, small molecules (e.g. the therapeutic molecules of this invention) will typically infiltrate as much as two to three centimeters beyond the tumor 25 margin. Alternatively, the therapeutic composition can be placed at the target site in a slow release formulation. Such formulations can include, for example, a biocompatible sponge or other inert or resorbable matrix material impregnated with the therapeutic composition, slow dissolving time release capsules or microcapsules, and the like.

30 Table 1 below summarizes the list of Sequence ID Numbers which appear in the application.

Table 1: Sequence listing

SEQ ID NO	Description	amino acid/nucleotide sequence
1	NKp46-Fc conjugate	Amino acids
2	NKp46D1-Fc conjugate	Amino acids
3	NKp46D2-Fc conjugate	Amino acids
4	NKp30-Fc conjugate	Amino acids
5	NKp44-Fc conjugate	Amino acids
6	NKp44DS-Fc conjugate	Amino acids
7	NKp44DL-Fc conjugate	Amino acids
8	NKp46-Fc conjugate	Nucleotides
9	NKp46D1-Fc conjugate	Nucleotides
10	NKp46D2-Fc conjugate	Nucleotides
11	NKp30-Fc conjugate	Nucleotides
12	NKp44-Fc conjugate	Nucleotides
13	NKp44DS-Fc conjugate	Nucleotides
14	NKp44DL-Fc conjugate	Nucleotides

5 SEQ ID NO:1 NKp46 (AJ001383 isoform a) protein

MSSTLPALLCVGLCLSQRISAQQQTLPKPFIWAEPHFMVPKEKQVTICCOGNYGAVEYQLHFEGLFAVD  
 RPKPERINKVFKYIPDMSRMAGQYSCIYRVGELWSEPSNLLDLVVTEMYDTPTLSVHPGPEVISGEKV  
 TFYCRLLTATSMFLLKEGRSSHVQRGYGVQAEFPLGPVTTAHRGTYRCFGSYNNHAWSFPSEVPKLLV  
 10 TGDIENTSLAPEDPTFPADTWGTYLLTETGLQKDHALWDHTAQDPEPKSSDKTHTCPCPAPEFEGAPSVF  
 LFPPPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDW  
 LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIIAVEWESNG  
 QPENNYKTPPVLSDGSFFLYSKLTVDKSRWQOGNVFCSVMHEALHNHYTQKSLSLSPGK

15 Black letters designate origin leader peptide  
 Underlined letters designate D1 region  
 Bold letters designate D2 region  
 Italic letters designate Fc region (234 amino acid)

20 SEQ ID NO: 2 NKp46-D1 stable amino acid seq.

MGMPMGSLQPLATLYLLGMLVASCLGRLRVQQQTLPKPFIWAEPHFMVPKEKQVTICCOGNYGAVEYQL  
 HFEGLFAVDRPKPERINKVFKYIPDMSRMAGQYSCIYRVGELWSEPSNLLDLVVTEMDPEPKSSDKTHTCPCPAPEFEGAPSVF  
 25 LFPPPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE  
 EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQV  
 SLTCLVKGFYPSDIIAVEWESNGQPENNYKTPPVLSDGSFFLYSKLTVDKSRWQOGNVFCSVMHEALH  
 NHYTQKSLSLSPGK

30 Black letters designate leader peptide of CD5  
 Underlined letters designate *KpnI* site (5 amino acid)  
 Bold letters designate D1 region  
 Italic letters designate Fc region (234 amino acid)

35 SEQ ID NO:3 NKp46-D2 stable amino acid seq.

MGMPMGSLQPLATLYLLGMLVASCLGRLRVPYDTPTLSVHPGPEVISGEKVTFYCRLLTATSMFLLKE  
 RSSHVQRGYGVQAEFPLGPVTTAHRGTYRCFGSYNNHAWSFPSEVPKLLVTDIENTSLAPEDPTF  
 WTGYLLTETGLQKDHALWDPEPKSSDKTHTCPCPAPEFEGAPSVFLFPPPKDTLMISRTPEVCVVDV  
 SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS

**AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDI~~A~~VEWE~~S~~NGQ~~P~~ENNYKTT~~P~~VLDSDGSFFLYSKL**  
**TV~~D~~KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK**

5      Black letters designate leader peptide of CD5  
 Underlined letters designate *KpnI* site (5 amino acid)  
 Bold letters designate D2 region (128 amino acid)  
 Italic letters designate Fc region (234 amino acid)

10     SEQ ID NO:4 NKp30 stable amino acid seq.

MGMPMGSLQPLATLYLLGMLVASCLGRLRVPLWVSQ~~P~~LEIRTLE~~C~~SSAFLPCSFNASQGRLAIGSVT~~W~~FR  
 DEV~~V~~PGKEVRNGTPEFRGRLA~~P~~ASSRF~~L~~HQ~~A~~ELHIRDVRGHDAS~~I~~YVCRVEVLGLGVGTGNGTRLVV  
 EKEHPQLGDPEPKSSDKTHTC~~P~~PCPAPEFEGAPS~~V~~FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF  
 NWYV~~D~~GVEVHN~~A~~KT~~K~~PREEQY~~N~~STYRV~~V~~SLTVLHQDWLNGKEYKCKVSNKALP~~A~~PIEKTISKA~~K~~GQ~~P~~RE  
 PQVYTLPPSRDELTKNQVSLTCLVKGFYPSDI~~A~~VEWE~~S~~NGQ~~P~~ENNYKTT~~P~~VLDSDGSFFLYSKLTVDKS  
 RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

15     Black letters designate leader peptide of CD5  
 Underlined letters designate *KpnI* site (5 amino acid)  
 Bold letters designate NKp30  
 Italic letters designate Fc region

20     SEQ ID NO:5NKp44 stable amino acid seq.

25     MGMPMGSLQPLATLYLLGMLVASCLGRLPQSKAQVLQSVAGQ~~T~~LT~~V~~RCQY~~P~~PTGSLYEKKGWCKEASA  
 LVCIRLV~~T~~SSK~~P~~R~~T~~V~~A~~WT~~S~~RFTI~~W~~DDPDAG~~F~~FTV~~T~~MDLREEDSGHYWCR~~I~~YRPSD~~N~~S~~V~~SK~~V~~RFYLVV  
 PASASTQTSWTPRDLVSSQ~~T~~QTQSCV~~P~~PTAGARQAP~~E~~P~~S~~PTI~~V~~P~~S~~Q~~P~~QN~~S~~TLRPGPAAPDPEPKSSDKT  
 HT~~C~~PPCPAPEFEGAPS~~V~~FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF~~N~~WYV~~D~~GVEVHN~~A~~KT~~K~~PRE  
 EQY~~N~~STYRV~~V~~SLTVLHQDWLNGKEYKCKVSNKALP~~A~~PIEKTISKA~~K~~GQ~~P~~RE~~P~~QVYTLPPSRDELTKNQV  
 SLTCLVKGFYPSDI~~A~~VEWE~~S~~NGQ~~P~~ENNYKTT~~P~~VLDSDGSFFLYSKLTVDKS~~R~~WQQGNVFSCSVMHEALH  
 NHYTQKSLSLSPGK

35     Black letters designate leader peptide of CD5  
 Underlined letters designate *KpnI* site (5 amino acid)  
 Bold letters designate NKp44 region  
 Italic letters designate Fc region (234 amino acid)

40     SEQ ID NO:6 NKp44-DS stable amino acid seq.

MGMPMGSLQPLATLYLLGMLVASCLGRLP~~S~~PASASTQTSWTPRDLVSSQ~~T~~QTQSCV~~P~~PTAGARQAP~~E~~  
 P~~S~~TI~~V~~P~~S~~Q~~P~~QN~~S~~TLRPGPAAPDPEPKSSDKTHTC~~P~~CPAPEFEGAPS~~V~~FLFPPKPKDTLMISRTPEVTC  
 VVVVDVSHEDPEVKF~~N~~WYV~~D~~GVEVHN~~A~~KT~~K~~PREEQY~~N~~STYRV~~V~~SLTVLHQDWLNGKEYKCKVSNKALP~~A~~  
 IEKTISKA~~K~~GQ~~P~~RE~~P~~QVYTLPPSRDELTKNQVSLTCLVKGFYPSDI~~A~~VEWE~~S~~NGQ~~P~~ENNYKTT~~P~~VLDSD  
 GSFFLYSKLTVDKS~~R~~WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

50     Black letters designate leader peptide of CD5  
 Underlined letters designate *KpnI* site (5 amino acid)  
 Bold letters designate NKp44-DS region  
 Italic letters designate Fc region (234 amino acid)

SEQ ID NO:7 NKp44-DL stable amino acid seq

55     MGMPMGSFQPLATLYLLGMLVASCLGRLPQSKAQVLQSVAGQ~~T~~LT~~V~~RCQY~~P~~PTGSLYEKKGWCKEASA  
 LVCIRLV~~T~~SSK~~P~~R~~T~~V~~A~~WT~~S~~RFTI~~W~~DDPDAG~~F~~FTV~~T~~MDLREEDSGHYWCR~~I~~YRPSD~~N~~S~~V~~SK~~V~~RFYLVV  
 PADPEPKSSDKTHTC~~P~~CPAPEFEGAPS~~V~~FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF~~N~~WYV~~D~~G

VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIASKAGQPREPVYTL  
 PPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGN  
 VFSCSVMHEALHNHYTQKSLSLSPGK

5

Black letters designate leader peptide of CD5  
 Underlined letters designate *KpnI* site (5 amino acid)  
 Bold letters designate NKp44-DL region  
 Italic letters designate Fc region (234 amino acid)

10

SEQ ID NO:8 NKp46 DNA seq. (AJ001383)

15 TCCCCACTGCTCAGCACTTAGGCCGGCAGAACATCTGAGCGATGTCTCCACACTCCCTGCCCTGCTCTGCG  
 TCGGGCTGTCTGAGTCAGAGGATCAGCGCCCAGCAGCAGACTCTCCAAAACCGTTCATCTGGGCCGA  
 GCCCCATTTCATGGTCCAAGGAAAAGCAAGTGACCATCTGTTGCCAGGGAAATTATGGGGCTGTGAA  
 TACCAAGCTGCACTTGAAGGAAGCCTTTGCCGTGGACAGACCAAAACCCCTGAGCGGATTAACAAAG  
 TCAAATTCTACATCCCGGACATGAACCTCCGCATGGCAGGGCAATACAGCTGCATCTATGGGGTTGGGA  
 GCTCTGGTCAGAGCCCAGCAACTTGCTGGATCTGGTGGTAACAGAAATGTATGACACACCCACCCCTCTG  
 GTTCATCTGGACCCGAAGTGAATCTGGGAGAGAAGGTGACCTCTACTGCCGTCTAGACACTGCAACAA  
 20 GCATGTTCTTACTGCTCAAGGAGGGAAAGATCCAGGCCACGTACAGCGGATACTGGGAAGGTCAGGCGGA  
 GTTCCCCCTGGGCCCTGTGACCACAGCCCACCGAGGGACATACCGATGTTGGCTCTATAACAACCAT  
 GCCTGGTCTTCCCCAGTGAGCCAGTGAAGCTCTGGTCACAGGCAGACATTGAGAACACACCAGCCTTGCAC  
 CTGAAGACCCCACCTTCTGCAGACACTTGGGGCACCTACCTTTAACACACAGAGACGGGACTCCAGAA  
 AGACCATGCCCTCTGGGATCACACTGCCAGGATCCGGAGCCAAATCTTCTGACAAAACACACATGC  
 25 CCACCGTCCCCAGCACCTGAATTGAGGGTGACCGTCAGTCTCCTCTCCCCAAAACCCAAGGACA  
 CCCTCATGATCTCCCGACCCCTGAGGTACATGCGTGGTGGACGTGAGCCACGAAGACCCCTGAGGT  
 CAAGTTCAAATGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGAACAAAGCCGGGGAGGAGCAGTAC  
 AACAGCACGTACCGTGTGGTCAGCGTCTCACCGTCTGCACCAGGACTGGCTGAATGGCAAGGAGTACA  
 AGTGCAAGGTCTCAAACAAGCCCTCCCAGCCCCATCGAGAAAACCATCTCAAAGCCAAGGGCAGCC  
 30 CCGAGAGGCCACAGGTGTACACCTGCCCTGGGATGAGCTGACCAAGAACCCAGGTCAGCCTGACC  
 TGCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGGAGCAATGGCAGCCGGAGAACAA  
 ACTACAAGACCACGCCCTCCCGTGTGGACTCCGACGGCTCCTCTACAGCAAGCTCACCGTGGAA  
 CAAGAGCAGGTGGCAGCAGGGGAACGTCTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCAACTAC  
 ACGCAGAAGAGCCTCTCCCTGTCTCCGGTAAATGA

35

SEQ ID NO:9 NKp46-D1 stable DNA seq. in pCDNA3.1

40 AAGCTT**GGCGCCACCATG**GGAATGCCCATGGGTCTCTGCAACCGCTGGCACCTTGTACCTGCTGGGA  
 TGCTGGTCGTTCCCTGCCTCGGACGGCTCAGGGTACCCAGCAGCAGACTCTCCAAAACCGTTCATCTG  
 GGCGAGCCCCATTTCATGGTCCAAGGAAAAGCAAGTGACCATCTGTTGCCAGGGAAATTATGGGGCT  
 GTTGAATACCAGCTGCACTTGAAGGAAGCCTTTGCCGTGGACAGACCAAAACCCCTGAGCGGATTA  
 ACAAAAGTCAAATTCTACATCCCGGACATGAACCTCCGCATGGCAGGGCAATACAGCTGCATCTATGGGT  
 TGGGGAGCTCTGGTCAGAGCCAGCAACTTGCTGGATCTGGTGGTAACAGAAATGGATCCGGAGCCAAA  
 TCTTCTGACAAAACACATGCCAACCGTGCCAGCACCTGAATTGAGGGTGACCGTCAGTCTTCC  
 45 TCTTCCCCCAAAACCAAGGACACCCCTCATGATCTCCGGACCCCTGAGGTACATGCGTGGTGGTGG  
 CGTGAGCCACGAAGACCCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAG  
 ACAAAAGCCGGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCTCACCGTCTGCACCAAG  
 ACTGGCTGAATGGCAAGGAGTACAAGTGAAGGTCTCAAACAAAGCCCTCCAGCCCCCATCGAGAAAAC  
 CATCTCCAAAGCCAAGGGCAGCCCCGAGAGGCCACAGGTGTACACCCCTGCCGGATGAGCTG  
 50 ACCAAGAACCCAGGTACGCCCTGACCTGCCCTGGTCAAAGGCTTCTATCCCAGCGACATGCCGTGGAGTGG  
 AGAGCAATGGCAGCCGGAGAACAAACTACAAGACCAACGCCCTCCCGTGTGGACTCCGACGGCTCCTTCTT  
 CCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTCTCATGCTCCGTGATG  
 CATGAGGCTCTGCACAACCAACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGTAAATGA

55 Black letters designate HindIII site

Open box designate Kozak seq. (with the G in position +4)

Underlined letters designate Start codon of the CD5 leader peptide

Bold letters designate CD5 leader peptide

Shaded letters designate *KpnI* site

Underlined letters designate D1 DNA seq.  
 Italic letters designate Fc DNA seq.

SEQ ID NO:10 NKp46-D2 stable DNA seq. in pCDNA3.1

5 AAGCTTGGCCACCATGGGGAATGCCATGGGTCTCTGCAACCGCTGCCACCTGTACCTGCTGGGA  
TGCTGGTCGCTCCTGCCTCGGACGGCTCAGGGTACCCTATGACACACCCACCTCTCGGTTATCCTGG  
ACCCGAGGTGATCTCGGGAGAGAAGGTGACCTCTACTGCCGCTAGACACTGCAACAAGCATGTTCTTA  
 CTGCTCAAGGAGGGAAAGATCCAGCCACGTACAGCGCGATACGGGAAGGGTCCAGGGAGTTCCCCCTGG  
 10 GCCCTGTGACCACAGCCCACCGAGGGACATACCGATTTGGCTCTATAACAAACCATGCCGGTCTTT  
 CCCCAGTGAGCCAGTGAGCTCCTGGTACAGGCACATTGAGAACACCAGCCTGACCTGAAGACCCC  
 ACCTTTCTGACACTGGGCACCTACCTTTAACACAGAGACGGGACTCCAGAAAGACCATGCCCTCT  
 GGGATCCGGAGCCAAATCTCTGACAAAACTCACACATGCCACCGTGGCCAGCACCTGAATTGAGGG  
 TGCACCGTCAGTCTCCTCTCCCCCAAAACCAAGGACACCCCTCATGATCTCCGGACCCCTGAGGTC  
 15 ACATGCGTGGTGGGACGTGAGCCACGAAGACCTGAGGTCAAGTCAACTGGTACGTGGACGGCGTGG  
 AGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAAACAGCACGCGTACCGTGTGGTCAGCGTCT  
 CACCGTCTCGACCAGGACTGGCTGAATGGCAAGGAGTACAGTGCAAGGTCTCCAAACAAAGCCCTCCCC  
 GCCCCCCATCGAGAAACCCATCTCCAAAGCCAAAGGGCAGCCGGCAAGGGCTGTACCCCTGGCC  
 20 CATCCCGGGATGAGCTGACCAAGACCCAGGTCAGCTGACCTGGCTGTCAAAGGGCTTTCTATCCAGCGGA  
 TCCGACGGCTCCTCTCCTACAGCAAGCTCACCGGTGGACAAAGAGCGAGGTGGACAGGGGAACGTCT  
 TCTCATGCTCCGTGATGCATGAGGTCTGCACAACCACTAACGCAGAGGCCTCCCTGTCTCCGG  
 TAAATGA

25 Black letters designate HindIII site

Open box designate Kozak seq. (with the G in position+4)

Underlined letters designate Start codon of the CD5 leader peptide

Bold letters designate CD5 leader

Shaded letters designate KpnI site

30 Underlined letters designate D2 DNA seq.

Italic letters designate Fc DNA seq.

SEQ ID NO:11 NKp30 stable DNA seq. in pCDNA3.1

35 AAGCTTGGCCACCATGGGGAATGCCATGGGTCTCTGCAACCGCTGCCACCTGTACCTGCTGGGA  
TGCTGGTCGCTCCTGCCTCGGACGGCTCAGGGTACCCCTCTGGGTGTCCAGCCCTTGAGATCGTA  
 CCTGGAAAGGGTCTCTGCTTCTGCTCTCATGCAGGAGATGGCATTGGCT  
 40 GTCACGTGGTTCCGAGATGAGGTCCCAGGGAGGAGGTGAGATGGCC  
 GCCTGGCCCCACTTGCTCTCCCGTAGCACGGCTGCATCCCGGACGTGC  
 AGGCCATGACGCCACGCATCAGTGCAGGGTGCTGGGCAGGATGG  
 ACTCGGCTGGTTGGGAGAACATCTCAGTGGGATTTGACAAACT  
 ACACATGCCACCGTCCCAGCACTGATTGAGGGTGCACGGCTGCG  
 45 CAAGGACACCCCTCATGATTCCGGACCTGAGGTGGACGCAGAGA  
 CCTGAGGTCAAGTCACTGGAGGGTGCATATGCAGACAGCGGG  
 AGCAGTACACGCAGTACGTGGTCAGCTCTGCACGGAGCA  
 GGAGTACAGTGCAGGTCCACAGCCCTCCATGAAACAGCA  
 GGGCAGCCCCGAGGCCAGGTGTACCTGCCCCATCCGGTCAGCA  
 50 GCCTGACCTGCTGGTCAAGGGTTCTATCCGGACGGTCAGCAGTCA  
 GGAGAACACTACAGACCGCTCCGTGGAGGACGGCAGTCA  
 ACCGTGGACAGAGGAGGTGGAGGGACGTTTCTAGCAGTCA  
 ACCACTACACGCAGAGGCTCCTGTCCGGGTAATG

55

Black letters designate HindIII site

Open box designate Kozak seq. (with the G in position +4)

Underlined letters designate Start codon of the CD5 leader peptide

Bold letters designate CD5 leader

60 Shaded letters designate KpnI site

Underlined letters designate 30 DNA seq.  
 Italic letters designate Fc DNA seq.

5 SEQ ID NO:12 NKp44 stable DNA seq. in pCDNA3.1

AAGCTTGCCGCCACCATGGGAATGCCCATGGGTCTCTGCAACCGCTGCCACCTGTACCTGCTGGGA  
 TGCTGGTCGCTTCCTGCCTCGGACGGCTCAGGGTACCCCAATCCAAGGCTCAGGTACTTCAAAGTGTGGC  
 AGGGCAGACGCTAACCGTGAGATGCCAGTACCCGCCACGGCAGTCTACGAGAAGAAAGGCTGGTGT  
 10 AAGGAGGCTTCAGCATGTGTGCATCAGTTAGTCACCAGCTCCAGGCCACGGCAGTCTACGAGAAGAAAGGCTGGTGT  
 CTCGATTCAAATCTGGGACCCCTGATGCTGGTCTTCACTGTCACCAGTGATGTGAGAGAGGA  
 AGACTCAGGACATTACTGGTGAGAATCTACGCCCTCTGACAACTCTGTCTCTAAGTCCGTAGATT  
 TATCTGGTGTATCTCCAGCCTCTGCCCCACAGACCTCTGGACTCCCCGCCACCTGGTCTTCA  
 15 AGACCCAGACCCAGAGCTGTGCCTCCACTGCAGGAGCCAGACAAGCCCTGAGTCTCCATCTACCAT  
 CCCTGTCCCTTCACAGCCACAGAACTCCACGCTCCGCCCTGCCCTGCAGCCCCGATCCGGAGCCAAA  
 TCTTCTGACAAAACTCACACATGCCCACCGTGCCAGCACCTGAATTTGAGGGTGCACCGTCAGTCTTC  
 TCTTCCCCCAAAACCCAAGGACACCCCTCATGATCTCCGGACCCCTGAGGTACATGCTGTTGGTGG  
 CGTGAGGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAG  
 20 ACAAAAGCCGGGGAGGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAAG  
 ACTGGCTGAATGGCAAGGGAGTACAAGTCAAGGTCTCCAAAAAAGCCCTCCAGCCCCATCGAGAAAAC  
 CATCTCAAAGCCAAGGGCAGCCCGAGAGCCACAGGTGACACCCTGCCCCATCCGGGATGAGCTG  
 ACCAAGAACCAGGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCAGCGACATGCCGTGGAGTGG  
 AGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCGTGCTGGACTCCGACGGCTCCTTCTT  
 25 CCTCTACAGCAAGCTGACCGTGGACAAGAGCAGGTGGCAGCAGGGAACGTCTTCATGCTCCGTGATG  
 CATGAGGCTCTGACAACCACTACAGCAGAAGAGCCTCTCCTGCTCCGGTAAATGA

Black letters designate HindIII site

Open box designate Kozak seq. (withtheGinposition+4)

Underlined letters designate Start codon of the CD5 leader peptide

30 Bold letters designate CD5 leader

Shaded letters designate KpnI site

Underlined letters designate NKp44 DNA seq.

Italic letters designate Fc DNA seq.

35

SEQ ID NO:13 NKp44-DS stable DNA seq. in pCDNA3.1

AAGCTTGCCGCCACCATGGGAATGCCCATGGGTCTCTGCAACCGCTGCCACCTGTACCTGCTGGGA  
 40 TGCTGGTCGCTTCCTGCCTCGGACGGCTCAGGGTACCCCTCCAGCCTCTGCCCACAGACCTCCT  
 GACTCCCCCGCACCTGGTCTTCACAGACCCAGACCCAGAGCTGTGTGCCTCCACTGCAGGAGCCAGA  
 CAAGCCCTGAGTCTCCACTTACCATCCCTGCTCCTCACAGCCACAGAACACTCCACGCTCCGCCT  
 CTGCAGCCCCGGATCCGGAGCCAATCTCTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGA  
 45 ATTCGAGGGTGCACCGTCAGGTCTCCTCCCCCCCAACCCAGGACACCCTCATGATCTCCGGACC  
 CCTGAGGTCACATGCCTGGTGGACGGTGAGCCACGAAGACCCTGAGGTCAAGTCAACTGGTACGTGG  
 ACGGGCGTGGAGGTGCATATGCCAAGACAAAGGCCGGGGGAGGAGCAGTACAACAGCACGTACCGTGTGGT  
 CAGCGTCTCACCGGTCTGCCACGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAA  
 50 GCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAGCCAAGGGCAGCCCGAGAGCCACAGGTGTACA  
 CCTGCCCCCCATCCGGGATGAGCTGACCAAGAACCCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTA  
 TCCCAGCGACATGCCTGGTGGAGGAGCAATGGGCAGCCGGAGAACAAACTACAAGGACCACGCCTCC  
 GTGCTGGACTCCGACGGCTCCTCTCCTCTACAGCAAGGCTACCGTGGACAAAGAGCAGGTGGCAGCAG  
 GGAACGTCTCTCATGCTCCTGTGATGCATGAGGCTCTGCCACAACCACTACAGCAGAAGAGCCTCTCC  
 GTCTCCGGTAAATGA

55 Black letters designate HindIII site

Open box designate Kozak seq. (withtheGinposition+4)

Underlined letters designate Start codon of the CD5 leader peptide

Bold letters designate CD5 leader

Shaded letters designate KpnI site

60 Underlined letters designate NKp44-DS DNA seq.

Italic letters designate Fc DNA seq.

SEQ ID NO:14 NKp44-DL stable DNA seq. in pCDNA3.1

5 AAGCTTGCCGCCACCATGGGAATGCCATGGGTCTCTGCAACCGCTGCCACCTGTACCTGCTGGGA  
 TGCTGGTCGCTTCTGCCTCGGACGGCTCAGGGTACCCCAATCCAAGGCTCAGGTACTTCAAAGTGTGGC  
 AGGGCAGACGCTAACCGTGAGATGCCAGTACCCGCCACGGGAGTCTCTACGAGAAGAAAGGCTGGTGT  
 AAGGAGGCTTCAGCACTTGTGATCAGGTTAGTCACCAGCTCCAAGCCCAGGACGGTGGCTTGGACCT  
 CTCGATTACAATCTGGGACGCCCTGATGCTGGCTTCACTGTCAACATGACTGATCTGAGAGAGGA  
 AGACTCAGGACATTACTGGTGAGAATCTACCGCCCTCTGACAACACTCTGTCTTAAGTCGGTCAGATT  
 10 TATCTGGTGGTATCTCCAGGGATCCGGAGCCAAATCTTCTGACAAAACCTCACACATGCCACCGTGCC  
 CAGCACCTGAATTGAGGGTGCACCGTCAGTCTTCTCTCCCTCAAACCCAAGGACACCCCTCATGAT  
 CTCCCGGACCCCTGAGGTACATGCGTGGTGGTGACGTGAGGCCACGAAGACCCCTGAGGTCAAGTTCAAC  
 TGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGT  
 15 ACCGTGTGGTCAGCGTCCCTCACCGTCTGCACCAAGGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGT  
 CTCCAACAAAGCCCTCCAGCCCCATCGAGAAAACCATCTCAAAGCCAAGGGCAGCCCCGAGAGCCA  
 CAGGTGTACACCCCTGCCCTCATCCGGATGAGCTGACCAAGAACCAAGGTCAAGCTGACCTGCCCTGGTCA  
 AAGGCTTCTATCCCAGCGACATGCCGTGGAGTGGGAGAGCAATGGCAGCCGGAGAACAACTACAAGAC  
 20 CACGCCTCCCGTGGACTCCGACGGCTCTTCTCCTACAGCAAGCTCACCGTGGACAAGAGCAGG  
 TGGCAGCAGGGGAACGTCTTCATGCTCCGTGATGCACTGAGGCTCTGCACAACCAACTACACGCAGAAGA  
 GCCTCTCCCTGTCTCCGGTAAATGA

Black letters designate HindIII site

Open box designate Kozak seq. (with the G in position +4)

25 Underlined letters designate Start codon of the CD5 leader peptide

Bold letters designate CD5 leader

Shaded letters designate KpnI site

Underlined letters designate NKp44-DL DNA seq.

Italic letters designate Fc DNA seq.

30

The following examples are presented in order to more fully illustrate certain  
 embodiments of the invention. They should in no way, however, be construed as limiting  
 the broad scope of the invention. One skilled in the art can readily devise many variations  
 35 and modifications of the principles disclosed herein without departing from the scope of the  
 invention.

## EXAMPLES

### 40 Experimental Methods:

#### Preparation of NKpi-Ig conjugates

Sequences encoding the extracellular portions of NKp30, NKp44 and NKp46 were  
 amplified by PCR from cDNA isolated from human NK clones. These PCR-generated  
 45 fragments were cloned into the mammalian expression vector containing the constant  
 region (Hinge+CH2+CH3) of a human IgG1 heavy chain. The Ig-conjugates (termed as

NKpi-Ig) were produced by transfection of mammalian cells (e.g. COS-7). Protein dimers were secreted from transfected cells (grown in medium without serum), and were purified from the supernatant using Protein-G columns. Protein-G binds only to Fc portion of the dimers made of Ig heavy chain constant regions; thus only the dimers of NKpi-Ig were 5 purified.

Preparation of NKpi-Ig stable clones for constant expression

Sequences encoding the extracellular portions of NKp30-Ig, NKp44-Ig, NKp46-Ig, NK46D2-Ig and CD99-Ig as a control protein were amplified by PCR from cDNA 10 isolated from human NK clones, using Kozak primer for high expression. These PCR fragments containing Kozak sequence and leader sequence were cloned into pedant 3.1-Ig vector. CHO cells were transfected with these expression vectors and were selected using G418 antibiotic. Selected clones were screened for highest protein production using 15 ELISA. High producer clones were re-cloned and screened again for highest protein production. One clone was adapted for special serum-free medium followed by optimization for growth in large-scale culture using spinner basket-Fibro cell (New Brunswick) or triple flasks. Supernatant were collected daily for purification on protein-G columns using FPLC.

20 Analysis of various prostate cancer cells for NCR binding

Expression of ligands to NCRs was quantitated by flow cytometry analysis of 25 NKpi-Ig binding to various prostate cancer cells. Cells were incubated with 10 micrograms of each NKpi-Ig followed by incubation with human Fc-specific-(PE)-conjugated goat-anti-human IgG. MFI indicates Median Fluorescence Intensity; MFI numbers were rounded to the nearest whole numbers. Results are representative of two independent experiments.

Testing the therapeutic efficacy of NKpi-Ig on prostate cancer and melanoma growth in vivo

30 PC-3 human prostate cancer cells were transfected with plasmid encoding the luciferase gene. Nude mice were injected with PC-3-luciferase cells and monitored for tumor growth twice a week. Tumor growth was monitored using whole-body imaging with a charged-coupled device camera. For real time monitoring of tumor development, mice were anesthetized and injected intraperitoneally with 50 mM luciferin (126 mg/Kg). 35 Bioluminescence was monitored 1 min later, using an intensified charged coupled device

camera (model U 6173-01; Hamamatsu, Hamamatsu, Japan). After establishment of tumor, NKpi-Ig was injected daily (0.25 mg / mouse / day) and the growth of tumors in treated and mock-treated mice was monitored.

5

**Example 1: Binding of NKpi-Ig to various cancer cells but not to normal peripheral blood lymphocytes (PBL).**

10 In order to measure the specific NKpi-Ig binding to various tumor cells, cells were incubated with different Ig-conjugates and stained with PE-conjugated goat anti-human Fc. As demonstrated in Figure 1, different human tumor cell lines (such as cell lines derived from Melanoma (1074mel, 1259mel, MELA1, 1106mel), Chronic Myelogenous Leukemia (CML) (K562), Prostate carcinoma (PC3-Luc, PC3, DU145), weakly EBV-transformed B cells (RPMI8866, 721.221)) were recognized by the various 15 lysis receptors NKp46, NKp44 and NKp30 conjugates. Primary tumor cells were also recognized by the various conjugates, including melanoma and CML cells. No specific NKpi-Ig binding was found in peripheral blood lymphocytes (PBL) normal cells, indicating the specific binding of NKpi-Ig to tumor cells. In addition, T cell lymphoma (Jurkat) and primary breast carcinoma were recognized mainly by NKp30 and NKp44 20 and to a lesser extent by NKp46.

25 The next step was to test conjugates containing the first domain of NKp46 (NKp46-D1-Ig) or the second domain of NKp46 (NKp46-D2-Ig) in their ability to bind specifically to tumor cells. Figure 2 demonstrates the binding of the NKp46-D1-Ig and NKp46-D2-Ig conjugates to Melanoma cell lines and prostate cancer cell lines. As can be observed, no significant binding of NKp46-D1-Ig was detected to any of the target cells tested. In contrast, binding of NKp46-D2-Ig was observed to the entire cell lines tested. These findings indicate that NKp46D2-Ig has a better binding capability comparing with 30 NKp46-Ig and NKp30-Ig. Table 2 summarizes the binding profile of NKp30 and NKp46 (30ug/ml) to various tumor cell lines as determined by FACS analysis. As control for Ig fusion protein CTLA-4 Ig was used for the carcinomas, in the case of lymphomas E7-Ig was used.

**Table 2:** Binding of NKp30 and NKp46 to tumor cell lines

Category	Designation	Histological Type	NKp46	NKp30
Breast	MDA-MB 231	Adenocarcinoma	Positive	Negative
Colon	HCT116	Adenocarcinoma	Negative	Negative
Colon	HT29	Adenocarcinoma	Positive	Positive
Lung	A-549	Large cell carcinoma	Negative	Negative
Prostate	LN-Cap	Metastatic carcinoma, androgen dependent	Positive	Positive
Prostate	PC-3	Carcinoma, androgen independent	Positive	Positive
B Lymphoma	SKW	EBV positive, B lymphoma	Negative	Negative
B Lymphoma	Raji	Burkitt's Lymphoma	Negative	Positive
B Lymphoma	Ramos	Burkitt's Lymphoma	Negative	Negative

5

**Example 2: Macrophage-mediated Antigen-Dependent Cellular Cytotoxicity of tumor cells with NKp30-Ig and NKp46D2-Ig**

As revealed from Figure 3, the binding of NKp46D2-Ig and NKp30-Ig conjugates to their unknown ligands on PC3 prostate cancer cells mediates the lysis of the cancer cells via macrophage-dependent lysis mechanism. In vitro killing of PC3 cells coated with the NKp30-Ig or NKp46D2-Ig conjugates by complement and NK cells was not observed.

**Example 3: In vivo tumor cell elimination after treatment with NKp30-Ig.**

15 Mice were inoculated S.C. with  $2 \times 10^6$  PC-3 human prostate cancer cells transfected with plasmid encoding the luciferase gene. Tumor growth was monitored using whole-body imaging with a charge-coupled device camera. After detectable tumors were established, mice were divided into two groups with similar tumor size distribution. One group received the test conjugate and the other received vehicle control for 3 weeks 20 and the mice were sacrificed. For the test group, NKp30-Ig was injected intraperitoneally daily (0.25 mg /mouse/day) for 3 weeks and the mice were sacrificed. The growth of tumors in treated and mock-treated mice was monitored twice a week. As revealed from Figure 4 and Table 3, the treatment with NKp30-Ig mediated tumor regression in prostate cancer-bearing nude mice.

**Table 3:** Tumor regression following the treatment with NKp30-Ig.

Treatment	Partial regression (less than 50%)	Regression (over 50%)	Progressive growth of tumor
<b>Control</b>	1/6	1/6	4/6
<b>NKp30-Ig</b>	1/7	5/7	1/7

5

Table 4 demonstrates the results following a multiple-dose treatment of NKp30-Ig compared to NKp46D2-Ig on PC3 tumors in nude mice.

10 **Table 4:** Tumor cell elimination following a multiple-dose treatment of NKp30-Ig and NKp46D2-Ig

Treatment	Complete response	Partial response	Progressive growth of tumor
<b>Control</b>	0/8	1/8	7/8
<b>NKp30-Ig</b>	7/17	5/17	5/7
<b>NKp46D2-Ig</b>	2/9	1/9	6/9

15 A large-scale experiment was designed to compare the effects of NKp30-Ig and NKp46D2-Ig on growth of tumors in nude mice injected with PC3 prostate cell line. The PC3 cells were injected and three weeks later when tumors were visible, treatments were initiated. As shown in Table 4, the treatment with NKp30-Ig results in complete or partial regression in about two thirds of the mice. Figure 5 illustrates the response obtained using the NKp30-Ig conjugate as revealed by the size of the tumor. Treatment with NKp46D2-Ig had no discernable effect on tumor growth in this set of experiments (Table 4).

20

**Example 4: NKp46D2-Ig binding is followed by its internalization to the intracellular domain.**

25 In order to examine whether the NKp46D2-Ig conjugate can be internalized into the target tumor cell, NKp46D2-Ig was incubated with 1106mel and PC3 cell lines followed by fluorescent dye, which can be monitored by confocal microscopy. Conditions suitable for internalization of receptors were applied. Figure 6 demonstrates that NKp46D2-Ig bind to its ligand on the cell surface of 1106mel cells and then is internalized into the intracellular domain. The same was demonstrated in PC3 cell line, NKp46D2-Ig is located in the intracellular domain after binding to its ligands on PC3 cell line.

**Example 5: Immunohistochemistry staining of NKp46D2-Ig and NKp30-Ig performed on normal and tumor Paraffin-embedded tissues**

5 Immunohistochemistry staining of NKp46D2-Ig and NKp30-Ig performed on different normal and tumor tissues was conducted. As demonstrated in Table 5, Paraffin-embedded tissues derived from tumors positively react with NKp46D2-Ig and NKp30-Ig. Normal tissues demonstrated negative results in the majority of the examined tissues. Pancreatic islet and chief cells in stomach fundus were the only normal cells that were stained by NKp46D2-Ig.

10

**Table 5: Immunohistochemistry staining of NKp46D2-Ig and NKp30-Ig performed on different normal and tumor paraffin embedded tissues.**

Tissue	Positive
Subcutaneous tissue	Angiosarcoma
Breast	Ductal carcinoma in situ
Breast	Infiltrating duct carcinoma
Lymph node	Hodgkin's disease
Bone	Osteosarcoma
Lung	Adenocarcinoma
Liver	Cholangiocarcinoma
Liver	Metastatic adenocarcinoma, rectum
Duodenum	Stromal tumor, malignant
Sigmoid colon	Adenocarcinoma
Rectum	Adenocarcinoma
Rectum	Mucinous carcinoma
Kidney	Renal cell carcinoma
Bladder	Transitional cell carcinoma
Myometrium	Leiomyoma
Ovary	Metastatic mucinous adenocarcinoma, appendix
Ovary	Mucinous cyst adenocarcinoma
Thyroid	Papillary carcinoma
Skin	Malignant melanoma

15

Pathologists use the Gleason system to evaluate the differentiation of the adenocarcinoma tissue in the prostate. It is based exclusively on the architectural pattern of the glands of the prostate tumor. It evaluates how effectively the cells of any particular cancer are able to structure themselves into glands resembling those of the normal

prostate. The ability of a tumor to mimic normal gland architecture is called its differentiation, and experience has shown that a tumor whose structure is nearly normal (well differentiated) will probably have a biological behavior relatively close to normal -- that is not very aggressively malignant. The principle is fairly simple, and Gleason  
5 grading from very well differentiated to very poorly differentiated. The lower the Gleason score, the better the patient is likely to survive.

Figure 7 demonstrates immunohistochemical staining with two prostate adenocarcinomas, one with score 8 and the second with score 6, the last prostate was a  
10 benign prostatic hyperplasia (BPH) that in elder man consider to be a "normal" prostate. As revealed from Figure 7, strong binding of NKp46D2-Ig and NKp30-Ig to the adenocarcinoma and not to the BPH was observed. It is important to note that when the BPH is in the vicinity of an adenocarcinoma it would be stained with NKp46D2-Ig and NKp30-Ig. These findings are unique because it means that the NKp30-Ig and NKp46D2-  
15 Ig conjugates can detect tumor-associated changes in the benign hyperplasia in the prostate.

The same pattern was found in melanoma and in pancreatic cancer. As demonstrated in Figure 8, NKp30-Ig and NKp46D2-Ig bind to malignant melanoma and not to benign nevus which is an early stage of potential melanoma. It is thus another  
20 example in which NKp46D2-Ig uniquely and selectively binds to the malignant cancers and to the normal tissues surrounding the tumor and not to benign lesions. Similarly, Figure 9 demonstrates that NKp46D2-Ig specifically recognizes the tissue derived from pancreatic cancer, one of the most lethal cancers in humans. NKp46D2-Ig binds specifically to pancreatic cancer cells that originate from acinar cells in the pancreas.

25

#### References:

1. Trinchieri, G. 1989. Biology of natural killer cells. *Adv Immunol* 47:187-376.
2. Long, E.O. 2002. Tumor cell recognition by natural killer cells. *Semin Cancer Biol*  
30 12:57-61.

3. Biassoni, R., C. Cantoni, D. Pende, S. Sivori, S. Parolini, M. Vitale, C. Bottino, and A. Moretta. 2001. Human natural killer cell receptors and co-receptors. *Immunol Rev* 181:203-214.
- 5 4. Bakker, A.B., J. Wu, J.H. Phillips, and L.L. Lanier. 2000. NK cell activation: distinct stimulatory pathways counterbalancing inhibitory signals. *Hum Immunol* 61:18-27.
- 10 5. Moretta, A., C. Bottino, M. Vitale, D. Pende, C. Cantoni, M.C. Mingari, R. Biassoni, and L. Moretta. 2001. Activating receptors and coreceptors involved in human natural killer cell-mediated cytosis. *Annu Rev Immunol* 19:197-223.
- 15 6. Ljunggren, H.G., and K. Karre. 1990. In search of the 'missing self': MHC molecules and NK cell recognition. *Immunol Today* 11:237-244.
7. McQueen, K.L., and P. Parham. 2002. Variable receptors controlling activation and inhibition of NK cells. *Curr Opin Immunol* 14:615-621.
- 20 8. Pessino A, Sivori S, Bottino C, Malaspina A, Morelli L, Moretta L, Biassoni R, Moretta A. Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. *J Exp Med.* 1998;188:953-960.
- 25 9. Vitale M, Bottino C, Sivori S, Sanseverino L, Castriconi R, Marcenaro E, Augugliaro R, Moretta L, Moretta A. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. *J Exp Med.* 1998;187:2065-2072.
- 30 10. Cantoni C, Bottino C, Vitale M, Pessino A, Augugliaro R, Malaspina A, Parolini S, Moretta L, Moretta A, Biassoni R. NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. *J Exp Med.* 1999;189:787-796.

11. Sivori S, Pende D, Bottino C, Marcenaro E, Pessino A, Biassoni R, Moretta L, Moretta A. NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or  
5 xenogeneic target cells. *Eur J Immunol.* 1999;29:1656-1666.
12. Costello RT, Sivori S, Marcenaro E, Lafage-Pochitaloff M, Mozziconacci MJ, Reviron D, Gastaut JA, Pende D, Olive D, Moretta A. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid  
10 leukemia. *Blood.* 2002;99:3661-3667.

15 It will be appreciated by a person skilled in the art that the present invention is not limited by what has been particularly shown and described hereinabove. Rather, the scope of the invention is defined by the claims that follow.

**CLAIMS:**

1. A polypeptide conjugate comprising:
  - (a) a target recognition segment comprising a Natural Killer cell receptor (NCR) or an active fragment thereof, wherein the NCR is selected from the group consisting of: NKp30 or a functional fragment thereof that binds to a cellular ligand expressed on the surface of a target tumor cell; and
  - (b) a second segment comprising an active agent capable of exerting a cytotoxic effect on the target cell.
2. The conjugate according to claim 1, wherein the active agent is selected from the group consisting of: a cytotoxic agent, an immunoglobulin (Ig) molecule and a fragment thereof.
3. The conjugate according to claim 2, wherein the active agent is the Fc fragment of the immunoglobulin molecule.
4. The conjugate according to claim 3, wherein the conjugate comprises NKp30 covalently attached to the Fc fragment of an Ig molecule.
5. The conjugate according to claim 4, having the amino acid sequence as set forth in SEQ ID NO:4 or functional fragments thereof.
6. An isolated polynucleotide encoding a polypeptide conjugate, the conjugate comprises:
  - (a) a target recognition segment comprising a Natural Killer cell receptor (NCR) or an active fragment thereof, wherein the NCR is selected from the group consisting of: NKp30 or a functional fragment thereof that binds to a cellular ligand expressed on the surface of a target tumor cell; and
  - (b) a second segment comprising an active agent capable of exerting a cytotoxic effect on the target cell.
7. The isolated polynucleotide according to claim 6, wherein the active agent is selected from the group consisting of: a cytotoxic agent, an Ig molecule and a fragment thereof.
8. The isolated polynucleotide according to claim 7, wherein the active agent is the Fc fragment of the immunoglobulin molecule.
9. The isolated polynucleotide according to claim 6, wherein the conjugate comprises NKp30 covalently attached to the Fc fragment of an Ig molecule.
10. The isolated polynucleotide according to claim 6, encoding the polypeptide sequence of SEQ ID NO:4.

11. The isolated polynucleotide according to claim 6, comprising SEQ ID NO:11 or fragments thereof.
12. A vector comprising the polynucleotide of any one of claims 6 to 11.
13. The vector according to claim 12, further comprising a regulatory element  
5 operably linked to said polynucleotide, the regulatory element is selected from the group consisting of: promoter, initiation codon, stop codon, polyadenylation signal, enhancer and selection marker.
14. The vector according to claim 12, wherein the vector is a plasmid or a virus.
15. The vector according to claim 14, wherein the vector is a virus selected from the  
10 group consisting of: adenoviruses, retroviruses and lentiviruses.
16. A host cell comprising the vector of any one of claims 12 to 15.
17. A host cell capable of expressing the polypeptide conjugate any one of claims 1 to  
5.
18. The host cell according to any one of claims 16-17, wherein the cell is eukaryotic  
15 or prokaryotic.
19. A pharmaceutical composition comprising as an active ingredient a polypeptide conjugate comprising:
  - (a) a target recognition segment comprising an NCR or an active fragment thereof, the NCR selected from the group consisting of: NKp30, or a functional fragment thereof, that binds to a cellular ligand expressed on the surface of a target tumor cell; and
  - (b) a second segment comprising an active agent that promotes the lysis of the target tumor cell; and
  - (c) a pharmaceutically acceptable carrier, stabilizer or diluent.
20. The pharmaceutical composition according to claim 19, wherein the active agent  
20 is selected from the group consisting of a cytotoxic agent, an immunoglobulin (Ig) molecule, and a fragment thereof.
21. The pharmaceutical composition according to claim 20, wherein the active agent is the Fc fragment of the immunoglobulin molecule.
22. The pharmaceutical composition according to claim 19, wherein the conjugate  
30 comprises NKp30 covalently attached to the Fc fragment of an Ig molecule.
23. The pharmaceutical composition according to claim 22, wherein the conjugate comprises the amino acid sequence as set forth in SEQ ID NO:4.

24. A method for treating a neoplastic disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a conjugate comprising:

5 (a) a target recognition segment comprising a Natural Killer cell receptor (NCR) or an active fragment thereof, the NCR is selected from the group consisting of: NKp46, NKp44, NKp30 or a functional fragment thereof that binds to a cellular ligand expressed on the surface of a target tumor cell; and

(b) a second segment comprising an active agent, the active agent capable of exerting a cytotoxic effect on said target cell,

10 the conjugate being capable of eliminating or inhibiting the growth of the tumor cells associated with the disease, thereby treating the disease.

25. The method according to claim 24, wherein the conjugate is according to any one of claims 1-5.

15 26. The method according to claim 25, wherein the malignant disease is any neoplastic disease is associated with a solid tumor or a non-solid tumor.

27. The method according to any one of claims 24 to 26, wherein the active agent is selected from the group consisting of: chemotherapeutic agents, radioisotopes, cytotoxins.

20 28. A method of inhibiting the growth of a tumor in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a polypeptide conjugate comprising:

25 (a) a target recognition segment comprising an NCR or an active fragment thereof, wherein said NCR is selected from the group consisting of: NKp46, NKp44, NKp30 or a functional fragment thereof that binds to a cellular ligand expressed on the surface of a target tumor cell; and

(b) an active segment comprising an active substance that promotes the lysis of the target tumor cell, thereby inhibiting the growth of the tumor in said subject.

29. The method according to claim 28, wherein the conjugate is according to any 30 one of claims 1-5.

30. The method according to claim 29, wherein the tumor is a solid tumor or a non-solid tumor.

31. The method according to any one of claims 28 to 30, wherein the active agent is selected from the group consisting of: chemotherapeutic agents, radioisotopes, cytotoxins.
32. The method according to claim 30, wherein the solid tumor is selected from the group consisting of: carcinoma, squamous cell carcinomas, adenocarcinomas, small cell carcinomas, melanomas, gliomas and neuroblastomas.
33. The method according to claim 30, wherein the non-solid tumor is selected from the group consisting of: B cell Lymphoma, T cell Lymphoma and Leukemia.
34. The method according to claim 31, wherein the cytotoxin is a plant-, a fungus- or a bacteria-derived toxin.
35. The method according to any one of claims 24 to 34, wherein the subject is a human subject.
36. A method of delivering a cytotoxic substance to a target tumor cell in a subject comprising administering to the subject a polypeptide conjugate comprising:
  - a. a target recognition segment comprising an NCR or an active fragment thereof, the wherein said NCR is selected from the group consisting of: NKp46, NKp44, NKp30 or a functional fragment thereof that binds to a cellular ligand expressed on the surface of a target tumor cell; and
  - b. an active segment comprising the cytotoxic substance,
- 20 37. The method according to claim 36, wherein the binding of the conjugate to the cellular ligand promotes the internalization of said conjugate within said target tumor cell, thereby delivering said cytotoxic substance to said target tumor cell.
38. The method according to any one of claims 36-37, wherein the tumor is a solid tumor or a non-solid tumor.
39. The method according to any one of claims 36 to 38, wherein the cytotoxic substance is selected from the group consisting of: chemotherapeutic agents, radioisotopes, cytotoxins.
- 30 40. The method according to claim 38, wherein the solid tumor is selected from the group consisting of: carcinoma, squamous cell carcinomas, adenocarcinomas, small cell carcinomas, melanomas, gliomas and neuroblastomas.
41. The method according to claim 38, wherein the non-solid tumor is selected from the group consisting of: B cell Lymphoma, T cell Lymphoma and Leukemia.

42. The method according to claim 39, wherein the cytotoxin is a plant-, a fungus- or a bacteria-derived toxin.
43. The method according to any one of claims 24, 28 or 36 wherein the conjugate is a polypeptide having the sequence set forth in SEQ ID NOS: 1-3.
- 5 44. The method according to any one of claims 24, 28 or 36 wherein the conjugate is a polypeptide having the sequence set forth in SEQ ID NOS: 5-7.

1/9




Figure 1




Figure 2

3/9





Figure 3

4/9



**Figure 4**

**BEST AVAILABLE COPY**

Figure 5





Figure 6



NKp46D2-Ig (37°C)  
NKp46D2-Ig (4°C)  
Control-Ig





Figure 7


8/9

Figure 8



BEST AVAILABLE COPY

Figure 9



BEST AVAILABLE COPY

## SEQUENCE LISTING

<110> NATSPEARS LTD.

<120> NK CELL RECEPTOR CONJUGATES FOR TREATING MALIGNANCIES

<130> NAP002-PCT

<150> US 60/431,728

<151> 2002-12-09

<160> 14

<170> PatentIn version 3.1

<210> 1

<211> 488

<212> PRT

<213> Homo sapiens

<400> 1

Met Ser Ser Thr Leu Pro Ala Leu Leu Cys Val Gly Leu Cys Leu Ser  
1 5 10 15

Gln Arg Ile Ser Ala Gln Gln Gln Thr Leu Pro Lys Pro Phe Ile Trp  
20 25 30

Ala Glu Pro His Phe Met Val Pro Lys Glu Lys Gln Val Thr Ile Cys  
35 40 45

Cys Gln Gly Asn Tyr Gly Ala Val Glu Tyr Gln Leu His Phe Glu Gly  
50 55 60

Ser Leu Phe Ala Val Asp Arg Pro Lys Pro Pro Glu Arg Ile Asn Lys  
65 70 75 80

Val Lys Phe Tyr Ile Pro Asp Met Asn Ser Arg Met Ala Gly Gln Tyr  
85 90 95

Ser Cys Ile Tyr Arg Val Gly Glu Leu Trp Ser Glu Pro Ser Asn Leu  
100 105 110

Leu Asp Leu Val Val Thr Glu Met Tyr Asp Thr Pro Thr Leu Ser Val  
115 120 125

His Pro Gly Pro Glu Val Ile Ser Gly Glu Lys Val Thr Phe Tyr Cys  
130 135 140

Arg Leu Asp Thr Ala Thr Ser Met Phe Leu Leu Leu Lys Glu Gly Arg  
145 150 155 160

Ser Ser His Val Gln Arg Gly Tyr Gly Lys Val Gln Ala Glu Phe Pro  
165 170 175

Leu Gly Pro Val Thr Thr Ala His Arg Gly Thr Tyr Arg Cys Phe Gly  
180 185 190

Ser Tyr Asn Asn His Ala Trp Ser Phe Pro Ser Glu Pro Val Lys Leu  
195 200 205

Leu Val Thr Gly Asp Ile Glu Asn Thr Ser Leu Ala Pro Glu Asp Pro  
210 215 220

Thr Phe Pro Ala Asp Thr Trp Gly Thr Tyr Leu Leu Thr Thr Glu Thr  
225 230 235 240

Gly Leu Gln Lys Asp His Ala Leu Trp Asp His Thr Ala Gln Asp Pro  
245 250 255

Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala  
260 265 270

Pro Glu Phe Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro  
275 280 285

Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val  
290 295 300

Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val  
305 310 315 320

Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln  
325 330 335

Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln  
340 345 350

Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala  
355 360 365

Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro  
370 375 380

Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr  
385 390 395 400

Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser  
405 410 415

Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr  
420 425 430

Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr  
435 440 445

Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe  
450 455 460

Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys  
465 470 475 480

Ser Leu Ser Leu Ser Pro Gly Lys  
485

<210> 2  
<211> 364  
<212> PRT  
<213> Homo sapiens

<400> 2

Met Gly Met Pro Met Gly Ser Leu Gln Pro Leu Ala Thr Leu Tyr Leu  
1 5 10 15

Leu Gly Met Leu Val Ala Ser Cys Leu Gly Arg Leu Arg Val Pro Gln  
20 25 30

Gln Gln Thr Leu Pro Lys Pro Phe Ile Trp Ala Glu Pro His Phe Met  
35 40 45

Val Pro Lys Glu Lys Gln Val Thr Ile Cys Cys Gln Gly Asn Tyr Gly  
50 55 60

Ala Val Glu Tyr Gln Leu His Phe Glu Gly Ser Leu Phe Ala Val Asp  
65 70 75 80

Arg Pro Lys Pro Pro Glu Arg Ile Asn Lys Val Lys Phe Tyr Ile Pro  
85 90 95

Asp Met Asn Ser Arg Met Ala Gly Gln Tyr Ser Cys Ile Tyr Arg Val  
100 105 110

Gly Glu Leu Trp Ser Glu Pro Ser Asn Leu Leu Asp Leu Val Val Thr  
115 120 125

Glu Met Asp Pro Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro  
130 135 140

Pro Cys Pro Ala Pro Glu Phe Glu Gly Ala Pro Ser Val Phe Leu Phe  
145 150 155 160

Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val  
165 170 175

Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe  
180 185 190

Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro  
195 200 205

Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr  
210 215 220

Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val  
225 230 235 240

Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala  
245 250 255

Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg  
260 265 270

Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly  
275 280 285

Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro  
290 295 300

Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser  
305 310 315 320

Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln  
325 330 335

Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His  
340 345 350

Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys  
355 360

<210> 3  
<211> 393  
<212> PRT  
<213> Homo sapiens

<400> 3

Met Gly Met Pro Met Gly Ser Leu Gln Pro Leu Ala Thr Leu Tyr Leu  
1 5 10 15

Leu Gly Met Leu Val Ala Ser Cys Leu Gly Arg Leu Arg Val Pro Tyr  
20 25 30

Asp Thr Pro Thr Leu Ser Val His Pro Gly Pro Glu Val Ile Ser Gly  
35 40 45

Glu Lys Val Thr Phe Tyr Cys Arg Leu Asp Thr Ala Thr Ser Met Phe  
50 55 60

Leu Leu Leu Lys Glu Gly Arg Ser Ser His Val Gln Arg Gly Tyr Gly  
65 70 75 80

Lys Val Gln Ala Glu Phe Pro Leu Gly Pro Val Thr Thr Ala His Arg  
85 90 95

Gly Thr Tyr Arg Cys Phe Gly Ser Tyr Asn Asn His Ala Trp Ser Phe  
100 105 110

Pro Ser Glu Pro Val Lys Leu Leu Val Thr Gly Asp Ile Glu Asn Thr  
115 120 125

Ser Leu Ala Pro Glu Asp Pro Thr Phe Pro Asp Thr Trp Gly Thr Tyr  
130 135 140

Leu Leu Thr Thr Glu Thr Gly Leu Gln Lys Asp His Ala Leu Trp Asp  
145 150 155 160

Pro Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro  
165 170 175

Ala Pro Glu Phe Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys  
180 185 190

Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val  
195 200 205

Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr  
210 215 220

Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu  
225 230 235 240

Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His  
245 250 255

Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys  
260 265 270

Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln  
275 280 285

Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu  
290 295 300

Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro  
305 310 315 320

Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn  
325 330 335

Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu  
340 345 350

Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val  
355 360 365

Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln  
370 375 380

Lys Ser Leu Ser Leu Ser Pro Gly Lys  
385 390

<210> 4  
<211> 382  
<212> PRT  
<213> Homo sapiens

<400> 4

Met Gly Met Pro Met Gly Ser Leu Gln Pro Leu Ala Thr Leu Tyr Leu  
Page 5

Leu Gly Met Leu Val Ala Ser Cys Leu Gly Arg Leu Arg Val Pro Leu  
20 25 30

Trp Val Ser Gln Pro Leu Glu Ile Arg Thr Leu Glu Gly Ser Ser Ala  
35 40 45

Phe Leu Pro Cys Ser Phe Asn Ala Ser Gln Gly Arg Leu Ala Ile Gly  
50 55 60

Ser Val Thr Trp Phe Arg Asp Glu Val Val Pro Gly Lys Glu Val Arg  
65 70 75 80

Asn Gly Thr Pro Glu Phe Arg Gly Arg Leu Ala Pro Leu Ala Ser Ser  
85 90 95

Arg Phe Leu His Asp His Gln Ala Glu Leu His Ile Arg Asp Val Arg  
100 105 110

Gly His Asp Ala Ser Ile Tyr Val Cys Arg Val Glu Val Leu Gly Leu  
115 120 125

Gly Val Gly Thr Gly Asn Gly Thr Arg Leu Val Val Glu Lys Glu His  
130 135 140

Pro Gln Leu Gly Asp Pro Glu Pro Lys Ser Ser Asp Lys Thr His Thr  
145 150 155 160

Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly Ala Pro Ser Val Phe  
165 170 175

Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro  
180 185 190

Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val  
195 200 205

Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr  
210 215 220

Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val  
225 230 235 240

Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys  
245 250 255

Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser  
260 265 270

Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro  
275 280 285

Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val

Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly  
 305 310 315 320

Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp  
 325 330 335

Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp  
 340 345 350

Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His  
 355 360 365

Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys  
 370 375 380

<210> 5

<211> 434

<212> PRT

<213> Homo sapiens

<400> 5

Met Gly Met Pro Met Gly Ser Leu Gln Pro Leu Ala Thr Leu Tyr Leu  
 1 5 10 15

Leu Gly Met Leu Val Ala Ser Cys Leu Gly Arg Leu Arg Val Pro Gln  
 20 25 30

Ser Lys Ala Gln Val Leu Gln Ser Val Ala Gly Gln Thr Leu Thr Val  
 35 40 45

Arg Cys Gln Tyr Pro Pro Thr Gly Ser Leu Tyr Glu Lys Lys Gly Trp  
 50 55 60

Cys Lys Glu Ala Ser Ala Leu Val Cys Ile Arg Leu Val Thr Ser Ser  
 65 70 75 80

Lys Pro Arg Thr Val Ala Trp Thr Ser Arg Phe Thr Ile Trp Asp Asp  
 85 90 95

Pro Asp Ala Gly Phe Phe Thr Val Thr Met Thr Asp Leu Arg Glu Glu  
 100 105 110

Asp Ser Gly His Tyr Trp Cys Arg Ile Tyr Arg Pro Ser Asp Asn Ser  
 115 120 125

Val Ser Lys Ser Val Arg Phe Tyr Leu Val Val Ser Pro Ala Ser Ala  
 130 135 140

Ser Thr Gln Thr Ser Trp Thr Pro Arg Asp Leu Val Ser Ser Gln Thr  
 145 150 155 160

Gln Thr Gln Ser Cys Val Pro Pro Thr Ala Gly Ala Arg Gln Ala Pro  
 165 170 175

Glu Ser Pro Ser Thr Ile Pro Val Pro Ser Gln Pro Gln Asn Ser Thr  
180 185 190

Leu Arg Pro Gly Pro Ala Ala Pro Asp Pro Glu Pro Lys Ser Ser Asp  
195 200 205

Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly Ala  
210 215 220

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile  
225 230 235 240

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu  
245 250 255

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His  
260 265 270

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg  
275 280 285

Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys  
290 295 300

Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu  
305 310 315 320

Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr  
325 330 335

Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu  
340 345 350

Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp  
355 360 365

Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val  
370 375 380

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp  
385 390 395 400

Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His  
405 410 415

Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro  
420 425 430

Gly Lys

<210> 6  
<211> 326

<212> PRT  
<213> Homo sapiens

<400> 6

Met Gly Met Pro Met Gly Ser Leu Gln Pro Leu Ala Thr Leu Tyr Leu  
1 5 10 15

Leu Gly Met Leu Val Ala Ser Cys Leu Gly Arg Leu Arg Val Pro Ser  
20 25 30

Pro Ala Ser Ala Ser Thr Gln Thr Ser Trp Thr Pro Arg Asp Leu Val  
35 40 45

Ser Ser Gln Thr Gln Thr Gln Ser Cys Val Pro Pro Thr Ala Gly Ala  
50 55 60

Arg Gln Ala Pro Glu Ser Pro Ser Thr Ile Pro Val Pro Ser Gln Pro  
65 70 75 80

Gln Asn Ser Thr Leu Arg Pro Gly Pro Ala Ala Pro Asp Pro Glu Pro  
85 90 95

Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu  
100 105 110

Phe Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp  
115 120 125

Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp  
130 135 140

Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly  
145 150 155 160

Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn  
165 170 175

Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp  
180 185 190

Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro  
195 200 205

Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu  
210 215 220

Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn  
225 230 235 240

Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile  
245 250 255

Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr  
260 265 270

Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys  
275 280 285

Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys  
290 295 300

Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu  
305 310 315 320

Ser Leu Ser Pro Gly Lys  
325

<210> 7

<211> 376

<212> PRT

<213> Homo sapiens

<400> 7

Met Gly Met Pro Met Gly Ser Phe Gln Pro Leu Ala Thr Leu Tyr Leu  
1 5 10 15

Leu Gly Met Leu Val Ala Ser Cys Leu Gly Arg Leu Arg Val Pro Gln  
20 25 30

Ser Lys Ala Gln Val Leu Gln Ser Val Ala Gly Gln Thr Leu Thr Val  
35 40 45

Arg Cys Gln Tyr Pro Pro Thr Gly Ser Leu Tyr Glu Lys Lys Gly Trp  
50 55 60

Cys Lys Glu Ala Ser Ala Leu Val Cys Ile Arg Leu Val Thr Ser Ser  
65 70 75 80

Lys Pro Arg Thr Val Ala Trp Thr Ser Arg Phe Thr Ile Trp Asp Asp  
85 90 95

Pro Asp Ala Gly Phe Phe Thr Val Thr Met Thr Asp Leu Arg Glu Glu  
100 105 110

Asp Ser Gly His Tyr Trp Cys Arg Ile Tyr Arg Pro Ser Asp Asn Ser  
115 120 125

Val Ser Lys Ser Val Arg Phe Tyr Leu Val Val Ser Pro Ala Asp Pro  
130 135 140

Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala  
145 150 155 160

Pro Glu Phe Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro  
165 170 175

Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val  
180 185 190

Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val  
 195 200 205

Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln  
 210 215 220

Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln  
 225 230 235 240

Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala  
 245 250 255

Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro  
 260 265 270

Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr  
 275 280 285

Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser  
 290 295 300

Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr  
 305 310 315 320

Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr  
 325 330 335

Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe  
 340 345 350

Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys  
 355 360 365

Ser Leu Ser Leu Ser Pro Gly Lys  
 370 375

<210> 8  
 <211> 1506  
 <212> DNA  
 <213> Homo sapiens

<400> 8	
tccccactgc tcagcactta ggccggcaga atctgagcga tgtcttccac actccctgcc	60
ctgctctgcg tcgggctgtg tctgagtcag aggatcagcg cccagcagca gactctccca	120
aaaccgttca tctgggccga gccccatttc atggttccaa agaaaaagca agtgaccatc	180
tgttgcagg gaaattatgg ggctgttcaa taccagctgc actttgaagg aagcctttt	240
gccgtggaca gacaaaacc ccctgagcgg attaacaag tcaaattcta catccggac	300
atgaactccc gcatggcagg gcaatacagc tgcatactac ggggggggaa gctctggta	360
gagcccagca acttgctgaa tctgggttca acagaaatgt atgacacacc caccctctcg	420
gttcatcctg gacccgaagt gatctcgaa gagaaggtga ctttctactg ccgtctagac	480
actgcaacaa gcatgttctt actgctcaag gagggaaatgt ccagccacgt acagcgccga	540

tacgggaagg	tccaggcggagttccccctg	ggccctgtga	ccacagccca	ccgagggaca	600
taccgatgtt	ttggctccta	taacaaccat	gcctggtctt	tccccagtga	660
ctcctggtca	caggcgacat	tgagaacacc	agccttgcac	ctgaagaccc	720
gcagacactt	ggggcaccta	ccttttaacc	acagagacgg	gactccagaa	780
ctctggatc	acactgccc	ggatccggag	cccaaatctt	ctgacaaaac	840
ccaccgtgcc	cagcacctga	attcgaggg	gcaccgtcag	tcttcctctt	900
cccaaggaca	ccctcatgat	ctcccggacc	cctgaggta	catgcgttgt	960
agccacgaag	accctgaggt	caagttcaac	tggtagtgg	acggcgtgga	1020
gccaagacaa	agccgcggga	ggagcagtac	aacagcacgt	accgtgttgt	1080
accgtcctgc	accaggactg	gctgaatggc	aaggagtaca	agtgcaaggt	1140
gcccctccag	ccccccatcga	gaaaaccatc	tccaaagcca	aagggcagcc	1200
caggtgtaca	ccctgcccc	atcccggat	gagctgacca	agaaccaggt	1260
tgcctggtca	aaggcttcta	tcccagcgcac	atcgccgtgg	agtggagag	1320
ccggagaaca	actacaagac	cacgcctccc	gtgctggact	ccgacggctc	1380
tacagcaagc	tcaccgtgga	caagagcagg	tggcagcagg	ggaacgtctt	1440
gtgatgcatg	aggctctgca	caaccactac	acgcagaaga	gcctctccct	1500
aaatga					1506

&lt;210&gt; 9

&lt;211&gt; 1110

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 9

aagcttgccg	ccaccatgg	aatgcccatt	gggtctctgc	aaccgctggc	cactttgtac	60
ctgctgggga	tgctggtcgc	ttccctgcctc	ggacggctca	gggtacccca	gcagcagact	120
ctcccaaaac	cgttcatctg	ggccgagccc	catttcatgg	ttccaaagga	aaagcaagt	180
accatctgtt	gccagggaaa	ttatgggct	gttgaataacc	agctgcactt	tgaaggaagc	240
ctttttgccg	tggacagacc	aaaacccct	gagcggattt	acaaagtcaa	attctacatc	300
ccggacatga	actcccgcat	ggcagggcaa	tacagctgca	tctatcggtt	tggggagctc	360
tggtcagagc	ccagcaactt	gctggatctg	gtggtaacag	aatggatcc	ggagccaaa	420
tcttctgaca	aaactcacac	atgcccaccc	tgcccagcac	ctgaattcga	gggtgcaccg	480
tcagtcttcc	tcttcccccc	aaaaccccaag	gacaccctca	tgatctcccg	gacccttgag	540
gtcacatgcg	tggtagtgg	cgtgagccac	gaagaccctg	aggtcaagtt	caactggtag	600
gtggacggcg	tggaggtgca	taatgccaag	acaaagccgc	gggaggagca	gtacaacagc	660
acgtaccgtg	tggtcagcgt	cctcaccgtc	ctgcaccagg	actggctgaa	tggcaaggag	720
tacaagtgc	aggtctccaa	caaagccctc	ccagccccc	tcgagaaaac	catctccaaa	780
gccaaagggc	agcccccgaga	gccacaggtg	tacaccctgc	ccccatcccg	ggatgagctg	840
accaagaacc	aggtcagcct	gacctgcctg	gtcaaaggct	tctatcccag	cgacatcgcc	900
gtggagtgg	agagcaatgg	gcagccggag	aacaactaca	agaccacgccc	tcccgtgctg	960

gactccgacg	gctccttctt	cctctacagc	aagctcaccg	tggacaagag	caggtggcag	1020
caggggaacg	tcttctcatg	ctccgtatg	catgaggcgc	tgcacaacca	ctacacgcag	1080
aagagcctct	ccctgtctcc	gggtaaatga				1110

<210> 10  
 <211> 1197  
 <212> DNA  
 <213> Homo sapiens

<400> 10						
aagcttgcgc	ccaccatggg	aatgcccatt	gggtctctgc	aaccgctggc	caccttgcac	60
ctgctgggaa	tgctggtcgc	ttcctgcctc	ggacggctca	gggtacccta	tgacacaccc	120
accctctcgg	ttcatcctgg	acccgaggtg	atctcgggag	agaaggtgac	cttctactgc	180
cgtctagaca	ctgcaacaag	catgttctta	ctgctcaagg	agggaaagatc	cagccacgta	240
cagcgcggat	acgggaagggt	ccaggcggag	ttccccctgg	gccctgtgac	cacagcccac	300
cgagggacat	accgatgttt	tggctcctat	aacaaccatg	cctggtcttt	ccccagtgag	360
ccagtgaagc	tcctggtcac	aggcgacatt	gagaacacca	gccttgcacc	tgaagacccc	420
acctttcctg	acacttgggg	cacctacatt	ttaaccacag	agacgggact	ccagaaagac	480
catgcccctc	gggatccgga	gcccaaattct	tctgacaaaaa	ctcacacatg	cccaccgtgc	540
ccagcacctg	aattcgaggg	tgcaccgtca	gtcttcctct	tccccccaaa	acccaaggac	600
accctcatga	tctcccgac	ccctgaggc	acatgcgtgg	tggtgacgt	gagccacgaa	660
gaccctgagg	tcaagttcaa	ctggtacgtg	gacggcgtgg	aggtgcataa	tgccaagaca	720
aagccgcggg	aggagcagta	caacagcag	taccgtgtgg	tcagcgtcct	caccgtcctg	780
caccaggact	ggctgaatgg	caaggagtac	aagtgcagg	tctccaacaa	agccctccca	840
gcccccatcg	agaaaaccat	ctccaaagcc	aaagggcagc	cccgagagcc	acaggtgtac	900
accctgcccc	catcccgga	tgagctgacc	aagaaccagg	tcagcctgac	ctgcctggtc	960
aaaggcttct	atcccagcga	catcgccgt	gagtggaga	gcaatggca	gccggagaac	1020
aactacaaga	ccacgcctcc	cgtgctggac	tccgacggct	ccttcttcct	ctacagcaag	1080
ctcaccgtgg	acaagagcag	gtggcagcag	gggaacgtct	tctcatgctc	cgtgatgcat	1140
gaggctctgc	acaaccacta	cacgcagaag	agcctctccc	tgtctccggg	taaatga	1197

<210> 11  
 <211> 1164  
 <212> DNA  
 <213> Homo sapiens

<400> 11						
aagcttgcgc	ccaccatggg	aatgcccatt	gggtctctgc	aaccgctggc	caccttgcac	60
ctgctgggaa	tgctggtcgc	ttcctgcctc	ggacggctca	gggtacccta	ctgggtgtcc	120
cagccccctt	agattcgta	cctgaaagg	tcttctgcct	tcctgcccctg	ctccttcaat	180
gccagccaag	ggagactggc	cattggctcc	gtcacgtgg	tccgagatga	ggtggttcca	240
gggaaggagg	tgaggaatgg	aaccccagag	ttcaggggcc	gcctggccccc	acttgcttct	300
tcccgtttcc	tccatgacca	ccaggcgtgag	ctgcacatcc	gggacgtgcg	aggccatgac	360

tcccgttcc	tccatgacca	gggctgag	ctgcacatcc	gggacgtgcg	aggccatgac	360
gccagcatct	acgtgtcag	agtggaggtg	ctgggccttgc	gtgtcgggac	aggaaatggg	420
actcggctgg	tggggagaa	agaacatcct	cagctagggg	atccggagcc	caaatcttct	480
gacaaaactc	acacatgccc	accgtgccc	gcacctgaat	tcgagggtgc	accgtcagtc	540
ttcctttcc	ccccaaaacc	caaggacacc	ctcatgatct	cccgacccc	tgaggtcaca	600
tgcgtggtgg	tggacgtgag	ccacgaagac	cctgaggtca	agttcaactg	gtacgtggac	660
ggcgtggagg	tgcataatgc	caagacaaag	ccgcggagg	agcagtacaa	cagcacgtac	720
cgtgtggtca	gcgtcctcac	cgtcctgcac	caggactggc	tgaatggcaa	ggagtacaag	780
tgcaaggct	ccaacaaagc	cctcccagcc	cccatcgaga	aaaccatctc	caaagccaaa	840
ggcagcccc	gagagccaca	ggtgtacacc	ctgccccat	cccggatga	gctgaccaag	900
aaccaggta	gcctgacctg	cctggtcaaa	ggcttctatc	ccagcgcacat	cgccgtggag	960
tgggagagca	atgggcagcc	ggagaacaac	tacaagacca	cgcctccgt	gctggactcc	1020
gacggctcct	tttccctcta	cagcaagctc	accgtggaca	agagcaggtg	gcagcagggg	1080
aacgtttct	catgctccgt	gatgcatgag	gctctgcaca	accactacac	gcagaagagc	1140
ctctccctgt	ctccggtaa	atga				1164

<210> 12  
 <211> 1320  
 <212> DNA  
 <213> Homo sapiens

<400> 12	aagcttgcgc	ccaccatggg	aatgcccatt	gggtctctgc	aaccgctggc	cacccatgtac	60
	ctgctgggaa	tgcgtggtcgc	ttcctgcctc	ggacggctca	gggtacccca	atccaaggct	120
	caggtacttc	aaagtgtggc	agggcagacg	ctaaccgtga	gatgccagta	ccgcggccacg	180
	ggcagttct	acgagaagaa	aggctgggt	aaggaggctt	cagcacttgt	gtgcattcagg	240
	ttagtcacca	gctccaagcc	caggacggtg	gcttggaccc	ctcgattcac	aatctggac	300
	gaccctgatg	ctggcttctt	cactgtcacc	atgactgatc	tgagagagga	agactcagga	360
	cattacttgt	gtagaatcta	ccgccttct	gacaactctg	tctctaagtc	cgtcagattc	420
	tatctggtg	tatctccagc	ctctgcctcc	acacagaccc	cctggactcc	ccgcgcaccc	480
	gtctcttcac	agacccagac	ccagagctgt	gtgcctccca	ctgcaggagc	cagacaagcc	540
	cctgagttct	catctaccat	ccctgtccct	tcacagccac	agaactccac	gctccgcct	600
	ggccctgcag	ccccggatcc	ggagccaaa	tcttctgaca	aaactcacac	atgcccaccc	660
	tgcccagcac	ctgaattcga	gggtgcaccg	tcagtcttcc	tcttcccccc	aaaacccaag	720
	gacaccctca	tgtatctcccg	gacccttgag	gtcacatgcg	tgggggtgga	cgtgagccac	780
	gaagaccctg	aggtcaagtt	caactggtac	gtggacggcg	tggaggtgca	taatgccaag	840
	acaaagccgc	gggaggagca	gtacaacagc	acgtaccgtg	tggtcagcgt	cctcaccgtc	900
	ctgcaccagg	actggctgaa	tggcaaggag	tacaagtgc	aggtctccaa	caaagccctc	960
	ccagccccc	tcgagaaaaac	catctccaaa	gccaaaggac	agcccccggaga	gccacaggtg	1020
	tacaccctgc	ccccatcccg	ggatgagctg	accaagaacc	aggtcagcct	gacctgcctg	1080

gtcaaaggct tctatcccag cgacatcgcc gtggagtgaa agagcaatgg gcagccggag 1140  
 aacaactaca agaccacgccc tccctgtctg gactccgacg gctccttctt cctctacagc 1200  
 aagctcaccg tggacaagag caggtggcag caggggaacg tcttctcatg ctccgtatg 1260  
 catgaggctc tgcacaacca ctacacgcag aagagcctct cccgtctcc gggtaatga 1320

<210> 13  
 <211> 996  
 <212> DNA  
 <213> Homo sapiens

<400> 13  
 aagcttgcgg ccaccatggg aatgcccattt gggtctctgc aaccgctggc cacccgttac 60  
 ctgctggggta tgctggtcgc ttcctgcctc ggacggctca gggtacccttc tccagccctt 120  
 gcctccacac agacccctcgt gactcccgcc gacccgttctt cttcacagac ccagaccagg 180  
 agctgtgtgc ctcccaactgc aggagccaga caagccctgt agtctccatc taccatccct 240  
 gtcccttcac agccacagaa ctccacgctc cgccctggcc ctgcagcccc ggatccggag 300  
 cccaaatctt ctgacaaaac tcacacatgc ccaccgtgcc cagcacctga attcgagggt 360  
 gcaccgtcag tcttccttccccccaaaa cccaggaca ccctcatgtat ctcccgacc 420  
 cctgaggtca catgcgttgtt ggtggacgtg agccacgaag accctgaggta caagttcaac 480  
 tggtacgtgg acggcgtggg ggtgcataat gccaagacaa agccgcgggaa ggagcagttac 540  
 aacagcacgt accgtgttgtt cagcgtcctc accgtctgc accaggactg gctgaatggc 600  
 aaggagtaca agtgcaaggt ctccaaacaaa gcccctccatc gccccatcga gaaaaccatc 660  
 tccaaagcca aagggcagcc ccgagagcca caggtgttaca ccctggggat atcccgggat 720  
 gagctgacca agaaccaggt cagcctgacc tgcctggtca aaggcttcta tcccaagcgac 780  
 atcgccgtgg agtgggagag caatggcag ccggagaaca actacaagac cacgcctccc 840  
 gtgctggact ccgacggctc tttcttcctc tacagcaagc tcaccgtggaa caagagcagg 900  
 tggcagcagg ggaacgttctt ctcatgtcc gtatgtatc aggctctgca caaccactac 960  
 acgcagaaga gcctctccct gtctccgggtt aaatga 996

<210> 14  
 <211> 1146  
 <212> DNA  
 <213> Homo sapiens

<400> 14  
 aagcttgcgg ccaccatggg aatgcccattt gggtctctgc aaccgctggc cacccgttac 60  
 ctgctggggta tgctggtcgc ttcctgcctc ggacggctca gggtacccttca atccaagggt 120  
 caggtaatccaaatgtggc agggcagacg ctaaccgtta gatgccagta cccggccacg 180  
 ggcagttctt acgagaagaa aggctgggtt aaggaggctt cagcacttgcgtt gtgcattcagg 240  
 ttagtcacca gctccaagcc caggacggtg gcttggaccc ttcgattcac aatctggac 300  
 gaccctgtatc ctggcttctt cactgtcacc atgactgatc tgagagagga agactcagg 360  
 cattactgtt gtatgtatca ccgccttctt gacaactctg tctctaagtc cgtcagattc 420  
 tatctgggtgg tatctccagc ggatccggag cccaaatctt ctgacaaaac tcacacatgc 480

ccaccgtgcc cagcacctga attcgagggt gcaccgtcag tcttcctctt ccccccaaaa	540
cccaaggaca ccctcatgat ctcccgacc cctgaggtca catgcgtgg ggtggacgtg	600
agccacgaag accctgaggt caagttcaac tgg tacgtgg acggcgtgga ggtgcataat	660
gccaagacaa agccgcggga ggagcagtac aacagcacgt accgtgtgg cagcgtcctc	720
accgtcctgc accaggactg gctaatggc aaggagtaca agtgcaggt ctccaacaaa	780
gccctcccag ccccatcga gaaaaccatc tccaaagcca aagggcagcc ccgagagcca	840
caggtgtaca ccctgcccc atccggat gagctgacca agaaccagg cagcctgacc	900
tgcctggtca aaggcttcta tccagcgac atcgccgtgg agtgggagag caatggcag	960
ccggagaaca actacaagac cacgcctccc gtgctggact ccgacggctc cttttccctc	1020
tacagcaagc tcaccgtgga caagagcagg tggcagcagg ggaacgttt ctcatgctcc	1080
gtgatgcattt aggctctgca caaccactac acgcagaaga gcctctccct gtctccgggt	1140
aaatga	1146